The stereochemistry and medicinal chemistry of 3-substituted 6,7-benzomorphans. by Ogundaini, Abiodun O.
        
University of Bath
PHD








If you require this document in an alternative format, please contact:
openaccess@bath.ac.uk
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 21. Oct. 2021




THE STEREOCHEMISTRY AND MEDICINAL 
CHEMISTRY OF 3-SUBSTITUTED 6,7- 
BENZOMORPHANS
THESIS
Submitted by Abiodun. O. Ogundaini 
B. Pharm., M. Phil(Ife) 
for the degree of Doctor of Philosophy 
of the University of Bath 
1983
This research has been carried out in the School of Pharmacy and 
Pharmacology of the University of Bath, under the supervision of 
Prof. R.T. Parfitt, B. Pharm., Ph.D., F.P.S., C. Chem., F.R.S.C.
COPYRIGHT
Attention is drawn to the fact that copyright of this thesis rests 
with its author. This copy of the thesis has been supplied on condition 
that anyone who consults it is understood to recognise that its copyright 
rests with its author and that no quotation from the thesis and no 
information derived from it may be published without the prior written 
consent of the author.
This thesis may be made available for consultation within the University 





INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a complete manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest.
ProQuest U 344454
Published by ProQuest LLC(2015). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States Code.
Microform Edition © ProQuest LLC.
ProQuest LLC 
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106-1346
TO THE MEMORY OF MY MOTHER 
MRS. S.T. OGUNDAINI 
who saw the beginning of this work but 
could not see the end.
(i)
ACKNOWLEDGEMENTS
I wish to express my sincere gratitude to Prof. R.T. Parfitt for 
his wonderful supervision and encouragement in the course of this work.
I would also like to express my thanks to the following: Drs. A.F. 
Casy and G. H. Dewar for their helpful discussion and readiness to help 
at all times; the School of Pharmacy, Brunswick Square, for the micro­
analyses of the compounds reported in the thesis; Dr. A.E. Jacobson 
of the National Institute of Health, Bethseda, for the mouse hot plate 
tests; Messrs R. Hartell, D. Wood and K. Smith for skilled technical 
assistance and to all my friends and colleagues who have all been helpful 
in more than one way.
I thank Mrs Judy Harbutt for typing this thesis and Eve Gonty 
for all her troubles.
Finally, I wish to express my sincere gratitude to the Association 




A brief survey of synthetic narcotic analgesics and newer 
developments in analgesic research is given. In particular, the 
chemistry and structure-biological-activity relationships in the
6 ,7-benzomorphan area is reviewed. The higher agonist potency 
of 4,5-dimethyl-6,7-benzomorphan over the cis-3,5-dimethyl isomer 
has been attributed tentatively to steric hindrance of the nitrogen 
lone electron pair in the latter by an equatorial 3-methyl group.
A more detailed investigation of this claim is therefore the subject 
of the present work.
A series of 3-monosubstituted and 3,3-disubstituted-6,7- 
benzomorphans have been synthesized and characterised. The con­
figuration of each is established by and n.m.r. spectroscopy. 
The differences in analgesic activity is explained by substituent 
participation in receptor interactions rather than by hindrance 
of nitrogen non bonding electrons, and this is considered in some 
detail.
2'-Hydroxyl analogues of 2-alkyl-cis-3,5-dimethyl-6,7-benzo- 
morphan and the corresponding 2,4,5-trimethyl isomer have been 
prepared and evaluated to complement the data on the 5,9-dimethyl 
isomers. The inactivity of 2'-hydroxyl-2,4,5-trimethyl-6,7- 
benzomorphan relative to the non-phenolic analogue has highlighted 
the need for further investigation in this area since, in general, 
the observation is that 2'-hydroxyl group leads to enhancement 
of activity in 6,7-benzomorphans. Some suggestions for additional
(iii)
work are also made.
Lastly, some potential analgesics in the 6,7-benzomorphan 
series having novel 2-amidino substituents have been prepared 
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Pain is a subjective experience that is interpreted as a sympto­
matic evidence of impending or actual tissue damage. The treatment 
of pain over the years has greatly been influenced by man's under­
standing of the subject. Some of the early methods used include 
herbal remedies, prayer and supplication, acupuncture, hypnosis, 
electrical stimulation and, later, analgesics.
However, no other pain reliever has stood the test of time in 
a manner comparable to opium - the dried exudate from the unripe seed 
capsules of the opium poppy Papaver soimiferum. The first reference 
to opium was by the Sumerians around 4000 B.C., when it was known 
as 'hul gil' or joy plant. The ancient Greeks and Romans used opium 
as a soporific and pain killer, and in Europe in the early 19th 
century opium preparations, such as the pill, and laudanum were 
widely used. Due to unreliability of these preparations a young 
German chemist Sertuner^ in 1805, isolated the active ingredient, 
the alkaloid morphine (1.1) from opium. By the mid 19th century, 
the use of pure morphine rather than the crude opium preparations 
had spread. Unfortunately, in addition to its analgesic action, 
morphine has other central effects: it causes the constriction of
the pupils, changes in mood and perception, and depression of the 
respiratory centre. Furthermore, prolonged usage leads to tolerance 
and physical dependence (addiction).
The recognition of this problem of addiction led to numerous 
efforts directed towards understanding the basic mechanisms of action
of the drug, and stimulated the continuing search for effective drug 
alternatives lacking the side effects characteristic of morphine.
1.2 Synthetic Analgesics
The determination of the total structure of morphine (1.1) by 
2Gulland and Robinson in 1925 was a milestone in the search for 




alkaloid and it was soon observed that simpler and effective morphine­
like compounds could be prepared which contained only a portion of 
the parent structure. Efforts in this direction have led to the 
following classes of analgesics: morphinans, benzomorphans, 4-aryl-
piperidines, 4-anilino piperidines, and .diphenylpropylamines. All 
of these classes, along with many other miscellaneous analgesics 
which cannot be easily classified, will be discussed briefly. A further
4.
group of analgesics, the oripavines first discovered by Bentley and 
Hardy^, are more complex than morphine and would not be discussed.
Derivatives of Morphine
Early attempts to find substitutes for morphine involved chemical 
modification of the naturally occurring alkaloid especially the 
chemically amenable ring C. Estérification or éthérification of 
the hydroxyl groups of morphine (1.1), gave compounds with reduced 
analgesic activity except in the case of heroin (1.2).
/ C H
OCRRCO
(1.2) R = CH^
(1.3) R = H
(1.4) R = CH^CH
4Diacetylmorphine (heroin, 1.2), first prepared by Wright was intro­
duced into clinical use as a morphine substitute, but was soon 
withdrawn in most countries because of its relatively high addiction 
liability. The "active" species is considered to be 6-acetylmorphine^. 
Other lower and higher acyl homologues (1.3 and 1.4) have since been 
shown to have similar analgesic potencies and high physical dependence 
capacity in monkeys^. However, typical of the effect produced by 
masking the phenolic hydroxyl is codeine (1.5), an analgesic about 




(1.5) R = CH^
(1.6) R = CHgCH
(1.7) R = -CH,-
Codeine is used mainly in the treatment of mild to moderate pain
and as a cough suppressant. Other phenolic ethers in clinical use
R Rare the ethyl (Dionin , 1.6), and benzyl (Peronin , 1.7) analogues.
Other chemical modifications to ring C include: oxidation, 
méthylation or replacement by halogen (chloromorphide) of the C-6 
hydroxyl group, and the introduction of new substituents such as 
methyl group in position 5 on ring C. The preparation of compounds 
incorporating one or more of the above modifications by Small and 
Eddy^, have led to several morphine derivatives with enhanced activity. 
Although none of these derivatives are demonstrably superior to 
morphine, at least two, hydromorphone (1.6) and hydrocodone (1.9), 




(1.6) R = H 
(1.9) R = CH.
6.
Other examples of useful morphine derivatives include the 14-hydroxy 
(oxymorphone; 1.10 partial formula), and 5-methyl (Metopon; 1.11 partial 
formula) analogues of hydromorphone.
HO
Me
(1.10, partial formula) (1.11, partial formula)
The replacement of the N-methyl group of morphine with an N-allyl
group gave nalorphine (1.12), a compound which reversed the actions
. ^  8-10 of morphine in humans
y C H 2 C H = C H 2
HO OH
(1.12)
Although inactive in rodent tests, nalorphine has been shown to 
possess considerable analgesic potency in primates, and limited 
dependence producing potential, in human stiadies. However, its
clinical utility was limited because of the psychotomimetic side 
effects at analgesic doses. Amongst the other important morphine 
based antagonists are the iV-allyl analogue (Naloxone, 1.13) and 
N-cyclopropylmethyl analogue (Naltrexone, 1.14) of oxymorphone
HO
HO
(1.13) R = -CH2CH=CH2
(1.14) R =
These two are pure antagonists because they block the effects of 
morphine without eliciting any analgesic effects.
Morphinans
The morphinans are a class of compounds lacking the furan oxygen 
bridge, the alcoholic hydroxyl and the alicyclic double bond of 
morphine. N-methylmorphinan was first synthesised by Grewe in 1946, 
and was found to be about one-fifth as potent as morphine as an 
analgesic. The laevorotatory isomer levorphanol (1.15) is 4 times 
as active as morphine, with the same level of addiction liability 
and is in clinical use today.
The interest in this class is centred on compounds of the 
agonist-antagonist type with little or no addiction liability, so
HO
(1.15) R = CH.
(1.16) R = -CHjc-C^H^
far considerable success has been achieved. For example, the N-
cyclopropylmethyl morphinan (cyclorphan, 1.16) is a potent analgesic
12and antagonist without addiction liability . More recently, in the
3,14-dihydroxy morphinans, oxilorphan (1.17), and butorphanol (1.16),





(1.16) R = CHg-c-C^Hg
T he former is a strong antagonist with a weak agonist activity
and butorphanol is a potent analgesic with moderate antagonist
13,14activity
Benzomorphans
The benzomorphan class .of compounds was first investigated by 
May and Murphy^^, and the main structural feature is that ring C 
of morphinans has been excised. The parent compounds in this class 
are 2'-hydroxy-2,5-dimethyl-6,7-benzomorphan (1.19) and the 2,5,9- 
trimethyl analogue (Metazocine, 1.20), structures in which the C- 




(1.20) R = CHg
(1.21) R = CH2CH=C(CH^)2
10.
The introduction of an extra methyl grcup at position 9 in (1.20) 
provided a third asymmetric centre and a new stereochemical dimension 
(possible cis- and trans-isomerism). In fact, the two possible isomers 
a-(cis) and ^-(trans)-metazocine have been isolated^^'^^. Several other 
benzomorphans have been studied and they have been shown to exhibit 
parallel structure-activity relationships with morphine and the mor­
phinans. In addition, some evidence of separation of analgesic and 
dependence producing effects in isomers (both diastereoisomeric and 
enantiomeric; see Chapter 2) was observed in this series^^. The N- 
dimethylallyl analogue of metazocine (pentazocine, 1.21) is in clinical 
use. A full discussion of the chemistry and structure-activity re­
lationships in the 5,7-benzomorphans follow in Chapter 2.
4-Arylpiperidines
The 4-arylpiperidine class owes its existence to the serendipitious 
19discovery of meperidine during studies of analogues of atropine.
In retrospect, it was found to be a further simplification of the
morphine molecule. Meperidine (pethidine, 1.22) is a narcotic anal-
21gesic used mostly for the relief of labour pain
(1.22) R = CH ____/ \
(1.23) R = -CH^CH^ y. yy
(1.24) R = -(CH^)^-NHPh
11.
Like heroin, it was initially thought to be non-addictive, but its
22dependence liability has since been established in animals and humans
Despite this, it is still one of the most widely used substitutes
•for morphine in moderate to severe pain situations. Other analogues
23of pethidine in clinical use include, Anileridine (1.23) and 
24Piminodine (1.24).
The replacement of the 4-carbethoxy (CO^Et) group of pethidine
with a ketone moiety gave the bemidone series. An example is keto-
bemidone (1.25), an analgesic twice as potent as pethidine and capable




Replacement of COOEt in pethidine with a propionoxy group (OCOEt)
gave the reversed esters of pethidine, which are again highly potent
compounds . A typical example is o-prodine {trans 3-Me | 4-Ph,
1.26) used clinically in obstetrics because of its rapid onset and
27short duration of action
Unlike morphine, the 6,7-benzomorphans and the morphinans, 





series by introducing N-substituents such as allyl and cyclopropyl- 
methyl groups was unsuccessful.
Examples include the iV-allyl derivatives of norpethidine (1.27)




However, a notable exception to this observation is the methyl ester




R = CH2— CH
Most of the work undertaken on this class of analgesics has been on 
the reversed esters because of their high potency. Several reviews 
on these investigations are available, particularly on the stereo­
chemical structure-activity relationships of the various piperidine 
ring C-alkylated derivatives^^ '
4-Anilinopiperidines
The prototype member of the 4-anilinopiperidine is the highly 
potent analgesic, fentanyl (1.30)
Fentanyl is a narcotic analgesic with morphine-like actions in 
mice and respiratory depression in cats and dogs^^. Due to its 
rapid onset and short duration of action, it is used in neurolept­
analgesia and in surgical analgesia when given with a major tran-
29quilizer such as droperidol . Structure activity relationships
14.
C H z C H g P h
(1.30)
studies of this class by Casy and others, have shown that the N-
32phenethyl group is essential for activity . This finding disting­
uished the class from the 4-phenylpiperidines where activity is 
still high in the N-CE^ analogues. In addition, the class has been 
shown to differ frcan morphine and the benzomorphans by the demon­
stration of significant agonist activity in the N-allyl and substituted 
allyl analogues. Other fentanyl derivatives substituted at the 
4-position by carboalkoxy (CC^R) as in pethidine, alkoxymethyl 
(CH^OR) and oxoalkyl (COR) as in ketobemidone, have been reported^^.
The most interesting of these analogues is sufentanyl (1.31), 
which displays high analgesic potency, a short duration of action 





The ultimate structural simplification of morphine was achieved
34with the synthesis of methadone, (1.32), an open chain analgesic
Ph OI IIR— CH— CHg— C— C— C2H5 I I
CH, Ph
(1.32) R = -N
CH.
CH.
(1.33) R = — N
(1.34) R = — N  Ô
16,
Methadone is as potent an analgesic as morphine but still has the 
same side effects, notably respiratory depression and dependence 
liability^^. However, because of its oral effectiveness and less 
severe withdrawal symptoms compared to morphine, it has wide appli­
cation in the treatment and rehabilitation of morphine and heroin 
addicts^^. Other members still in clinical use are the piperidino- 
analogue (Dipipanone, 1.33) and the morpholino-analogue (Phenoxadone,
Miscellaneous groups
There are several other interesting structures with opiate
activity which do not fit clearly into any of the above classes.
Examples include the thiambutenes, represented by 3-dimethylamino-
1, 1-bis (2-thienyl)-l-butene (1.35), a morphine-like analgesic less
effective than morphine in humans, but with the same level of 
38abuse liability and the benzylamines, typified by (-)-cis-2-
? x C H j
C = C H - C H - N ,
(1.35)
17
(dimethylamino-m-hydroxybenzyl) cyclohexanol (1.36), which is twice
as potent as morphine as an agonist and about equal to nalorphine as





Unfortunately, despite the vast number of synthetic analgesics 
prepared, the goal of obtaining an analgesic without the dependence 
producing, and other undesirable side-effects of morphine remains 
elusive. In those agents where a degree of separation between 
analgesia and dependence is observed, other side effects, such as 
respiratory depression, still express themselves. Consequently, 
interest in the whole field of analgesics remains as intense now 
as it has been at any time in the last twenty years.
1.3 The Opiate Receptor
The term "opiate receptor" is used to designate areas in the 
brain and peripheral tissues having specific affinity for opiate 
agonists and antagonists, and thus eliciting a pharmacological 
response. Long before the unequivocal demonstration of the existence
18.
of the opiate receptor, the circumstantial evidence in favour of
40 41their existence was substantial ’ . Such evidence was obtained
from structure-activity relationship (SAR) studies and includes
a) The overall similarities in the nature of opiate agonists, 
typified by the presence of an aromatic group and a positively 
charged nitrogen atom capable of ionic bonding, all suggestive 
of an interaction with a chemically and geometrically comple­
mentary site.
b) The stereospecificity of agonists, both pharmacological and steric, 
in particular a discrimination between the dextrorotatory (d-)
and laevorotatory (1-) isomers.
c) The effects of slight structural changes that can convert agonists 
into antagonists capable of abolishing the analgesic and all
other effects of the agonist.
The direct identification of the receptor sites remained elusive
for some time, whilst the results from the SAR studies were used to
speculate on the nature of opioid receptor(s) and encouraged the
proposal of models for the binding of opiates to the receptor. An
42example of this is the classical studies of Beckett and Casy . In
this model, a receptor surface was formulated which possessed a flat
lipophilic surface binding the aromatic ring, a cavity to accommodate
the hydrocarbon portion of the piperidine ring, and an anionic amine
binding site. However, this concept of a 'rigid' receptor was sub-
43sequently modified by Portoghese to envisage a receptor with a 
degree of flexibility in which 'induced fit' is a major factor in 
opiate-receptor interactions.
19.
More refined models have been proposed which contain an additional
lipophilic binding site, designed to rationalise the superior potency
44,45of oripavines and fentanyl-related analgesics . More recently,
the addition of a different loci for amine binding has emerged to 
accommodate agonist and antagonist receptor states^^'^^.
Efforts directed towards identifying the opiate receptor
achieved some breakthrough with the proposal of stereospecific
48 49 50binding by Goldstein in 1971 . Along with several other workers, '
he demonstrated the existence of an opiate receptor in the midbrain 
and peripheral nervous tissues of vertebrates, which is capable of 
stereospecifically binding morphine, other potent agonists,and anta­
gonists such as naloxone. The presence of opiate receptors in the 
intestine has also been demonstrated, and at the subcellular level 
opiate receptors are confined specifically to synaptic membranes^^. 
Further, attempts to characterise the opiate receptor, though un­
successful, led to the suggestion of the presence of a thiol residue
52at, or near, the receptor
The identification of the opiate receptor allowed a direct 
examination of opiate-receptor interactions. The bindings observed 
in the guinea pig ileum, rat brain and cell cultures of neuroblastoma
X glioma hybrids have been correlated with pharmacological activity
53 54of both agonists and antagonists . The differences observed in
the in vitro binding of agonists and antagonists in the presence of
sodium ions has led to the proposal of the allosteric model of the
opiate receptor^^'^^. This model presumes that the opiate receptor
can assume two different conformations, and that sodium ion plays
a crucial role in effecting a transition between the two states^ .
20.
The antagonist is presumed to act on the sodium bound form, and the 
agonist on the non-sodium bound form, to elicit their respective 
actions. This theory explains the in vivo superiority of antagonists 
over agonists, but leaves a number of questions unanswered. Based on 
binding studies and further pharmacological evidence, however, the 
possible existence of further discrete and non-interconvertible 
receptors has been proposed^^.
The demonstration of the existence of opiate receptors in the 
nervous system and peripheral tissues raised questions about the 
functions they serve, as it is clear that receptors do not exist in 
the body for the sole purpose of receiving exogenous drugs. The quest 
for a rational explanation for their existence inspired an intensive 
research effort which, in 1975, culminated in the demonstration in 
pig brain extract^^'^^ and human cerebrospinal fluid^^ of endogenous 
opioid substances. Hughes et a l subsequently isolated from the 
brain of pigs, two related pentapeptides which they named enkephalins,
The two peptides have the same amino acid sequence but differ 
only in their C-terminal amino acid residue, these being methionine 
(Met-enk., 1.37) and leucine (Leu-enk., 1.36).
Tyr-Gly-Gly-Phe-Met 
1 2 3 4 5
(Met-enk., 1.37) Tyr-Gly-Gly-Phe-Leu
1 2 3 4 5
(Leu-enk., 1.36)
21.
Met-enk. is a potent agonist in the mouse vas deferens (x20 normorphine)
and the guinea pig ileum (xl normorphine) tests , both activities
being completely reversed by naloxone. Leu-enk exhibits a similar
profile of activity but is less potent. The enkephalins have a short
duration of action compared to morphine^^ due to metabolic lability,
59 64as evident from rapid dénaturation by tissue homogenates '
The recognition that Met-enk. was identical to the fragment
61 - 65 of the pituitary hormone g-lipotropin (6 -LPH) led to an
extensive examination of the pituitary extracts for opiate activity
and this led to the isolation of high molecular weight peptides, the
endorphins^^'^^. Three of these polypeptides have been isolated:
o_-endorphin (_3 ~LPH^^ ^^) , ^-endorphin (^-LPH^^ ^^) and ^-endorphin
(^-LPH^^ ^^). Of these, only the and ^  endorphins have analgesic
activity, with ^-the more active of the two. g-endorphin has been
shown to be 3x more active than morphine when injected intravenously,
and its effects are blocked by naloxone^^. In contrast to the
enkephalins, however, ^-endorphin is relatively stable to brain
peptidases. The influence on activity of the C-terminal tetrapeptide
(Lys - Lys - Gly - Glu- ) of 3 endorphin has been studied, do dy yo y_L —
The removal of residues 90 and 91 had little effect, whilst removal 
of residues 8 8  and 89 (Lys-Lys) had a profound effect on opiate 
activity as measured by binding to brain synaptosomal membranes and 
tail flick assays in rats^^.
The idea that structures based on natural opiates might avoid 
the physical dependence and tolerance inherent in narcotic analgesics 
has stimulated considerable interest in synthetic analogues of 
enkephalins. Unfortunately, however, both Met-enk. and 3-endorphin
22.
were shown to cause typical opiate withdrawal symptoms after chronic
• Æ • • 4- . , 69,70infusions into rat brain
Nevertheless, a number of structure-activity relationship studies
have been carried out on the enkephalins. The need for a correct
absolute stereochemistry (L) for tyrosine (Tyr^) has been demonstrated,
Replacement with D-Tyrosine as in (D-Tyr^)-Met-enkephalin led to
loss of opiate activity in the receptor binding studies and vas
deferens assay^^. The importance of the free phenolic and amino
groups of tyrosine have also been demonstrated. The des-amino Tyr-
72analogues of Met- and Leu-enkephalins were inactive , and removal 
of the -OH group of the tyrosine residue had a pronounced adverse 
effect on activity^^. Masking of the tyrosine amino group by 
^-carbamylation or Tyr-OH by 0-benzylation similarly abolished or 
reduced the opiate properties of 3 -endorphin.
Since the primary mode of degradation of enkephalins has been 
shown to be the cleavage of Tyr-Gly amide bond,^^'^^ increased 
resistance to enzymatic degradation has been achieved by substituting 
a D-amino acid for glycine at the 2-position, and also by forming 
the amide at the carboxylic acid terminal of methionine^^,-
2For example, the D-Ala -enkephalin derivative was particularly
resistant to peptidyl enzymes while retaining the properties of the
77natural enkephalin
Other stable synthetic analogues of Met-enk. with longer duration 
of action and increased potency were obtained by altering the terminal
23
5 2Met-COOH to CH^OH (Met -ol) substituting Gly by D-A1&, oxidation of
4 78Met. sulphide to sulphoxide, and N-methylation of the Phe -residue
2 5The peptide with D-Ala -Met -ol sequence showed subcutaneous (s.c.)
activity as well as prolonged intravenous (i.v.) analgesic potency.
2 4The compound (1.39) incorporating all the changes D-Ala -MePhe -Met-
(O)^-ol showed analgesic activity even after oral administration and 
was many times more active than Met-enk. and morphine in mice following 
i.v.injection.
O  O  O
H N -C H -C -N H -C H -C  -N H  CH^C NCH C NH CH CH OH
C H 3 C H j  ( Ç H 3)
c A o
(1.39)
Though the goal of producing structures based on endogenous opioids 
without physical dependence and tolerance inherent in narcotic 
analgesics has not been achieved, analogues of peptide opioids have 
been invaluable in studying both the central and peripheral actions 
of analgesics, mapping distribution of opiate receptors in various 
tissues and in defining the diverse roles now known to be associated 
with the enkephalins and endorphins vis â vis other narcotic 
analgesics.
24.
Concept of multiple receptors
The different pharmacological profile observed with a wide variety 
of narcotic analgesics (peptide and non-peptide) gave rise to the 
hypothesis of the existence in the brain of multiple opiate receptors 
(putative 6, y, k , z , and 0)^9,80^ Such a concept might help to 
explain the roles played by the enkephalins and endorphins, and 
tentatively provide explanations for seme anomalous pharmacological 
observations with opioid peptides. For example, the concept helped 
to explain why the potency of naloxone as an antagonist of morphine 
is comparable to that of enkephalin in the mouse vas deferens but 
not in the guinea pig ileum
Extensive competitive binding assays in guinea pig brain homo- 
82genate , along with comparative pharmacology in the guinea pig
83ileum assay and mouse vas deferens assay , gave compelling evidence
for at least two distinct receptors: y (morphine) and <T (enkephalin).
More recent studies suggest the existence of two further receptor
entities: the e, proposed for the opiate receptor in the rat vas
deferens with pronounced selectivity for ^ - e n d o r p h i n ^ ^ , and,
86
K-receptor for which brema^ocine (1.40) is an agonist
(1.40)
25.
Several research workers have studied specific responses mediated 
by each opiate receptor. Reports^^'^^ suggest that p and/or K-receptors 
are responsible for analgesic effects, while Ô and a receptors 
mediate other effects. The prototype agonists for these receptors 
are, morphine (y), ketocyclazocine (k ) and iV-allylnorcyclazocine (a). 
Naloxone is the prototype p-antagonist and the novel benzomorphan








This characterisation of receptors and the ligands with which
they possibly interact has helped to explain some of the different
pharmacological profiles noticed for opiates (peptides and non-peptides)
89For example, Hutchinson et al. have noticed in a study of certain 
benzomorphans that an enhanced guinea pig ileum/mouse vas deferens 
potency ratio, coupled with poor reversal of activity by naloxone, 
is predictive of interactions at the < receptor and, hence, a low 
morphine-like dependence liability.
The demonstration and location of opiate receptors, and the
26.
ligands with which they interact (the enkephalins and endorphins), 
was a milestone in analgesic research. It provides not only a rational 
explanation for some hitherto unexplained pharmacological observations, 
but promises an understanding of the mystery of tolerance and depen­
dence. Though attempts to obtain the 'ideal' analgesic based on the 
endogenous opiates has been unsuccessful, there is hope that further 
studies with both synthetic and endogenous opioids will lead 
ultimately to accurate dissection of opioid pharmacology and structure 








The preparation of the first compound containing the benzomorphan
90ring system {2.1), was reported by Barltrop in 1947
NH
(2.1)
There are two common numbering systems for the parent ring of benzo­
morphans. l,2,3,4,5,6-Hexahydro-2,6-methano-3-benzazocine, (2.2), 
as described in the "Ring Index" and Chemical Abstracts, and 6,7-benzo-
morphan {2.3), the nomenclature suggested by Barltrop and adopted 




The latter will be used throughout this thesis.
2.2 Synthesis and Stereochemistry
The various synthetic approaches to 6 ,7-benzomorphans have
91,92been extensively reviewed . The two most important routes, the
tetralone route and Crewe's cyclisation are briefly discussed, 
highlighting the advantages and disadvantages of their use. A brief 
mention will bè made of other routes.
The tetralone routes
The application of this route to the synthesis of 6,7-benzoraorphans
90followed the initial work of Barltrop in the synthesis of (2.4), 
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(2 .8 ) (R = H; 2.9a)
SCHEME 1
31.
(2.9a) (Scheme 1). Alkylation of 3 ,4-dihydro-1-methy1-2(IH )-naphth- 
alenone (2.5), with ^-dimethylaminoethyl chloride gave (2.6), which 
was brominated and cyclised in base to the methiodide (2.6) . Dry 
distillation and reduction of (2.6) afforded the benzomorphan (2.9a).
The overall yield was, however, very poor due to the low yields of 
some of the reaction steps in the sequence; for example, (2.6) (2. 9)
Alternatively, a longer, but higher yield, route starting with
2-phenylpropionitrile (2.10) was used. (See Scheme 2). In this scheme,
2-phenyl propionitrile was converted into the tetralone (2.13), which
was sequentially converted to the benzomorphan (2.9a) in 5% yield.
However, the use of the tetralone route is limited largely to the
93-95preparation of 5-substituted benzomorphans , as attempts to
prepare the trimethyl derivatives have.been u n s u c c e s s f u l ^ ^ F o r
example, the key aminoketone (2.15), in the preparation of 2,5,9-tri-
methyl-6 ,7-benzomorphan (2.16), was unreactive under Knoevenagel
98conditions with either malonitrile or methyl cyanoacetate
Me
2.15








{2 .10) {2 .11 )
(1) MeO CCH CN,NH OAc,
_____________ HOAc











(1) 33. HBr (1 ) dry distil
(2.13) HCl, EtOAc(2) Br HOAc






2-dimet±iyl-aminopropane (2.17), in the attempted preparation of
2 ,3,5-trimethyl-6,7-benzomorphan, affected the nature and yield of
the products due -to the formation of two carbonium ion species.
(see Scheme 3). Thus, l-chloro-2-dimethylaminopropane in the base
form cyclises to the quaternary salt (2.18). The carbonium ion
species from (2.18) is a mixture of (2*19) and (2.20) which affects
the alkylation stages. Reaction of these ions with the sodium salt
of (2.5) will lead to a mixture of products and low yields. This
97has in fact been found to be the case
(2.17)
+ CH2— CH —  CHj
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This method is analogous to Grewe's synthesis of morphinans,
and is based upon the acid catalysed cyclisation of appropriately
99,100substituted tetrahydropyridines' For example, (2.21) to (2.22)
(2.21)
(2.22)
The tetrahydropyridine precursor may be obtained in either of two 
ways :
a) from the reaction of an appropriate Grignard reagent with a 
pyridinium salt; and
b) via a Steven's rearrangement of the corresponding benzylalkyl- 
pyridinium salts^^^.
In the former (see Scheme 4), the benzyl Grignard reagent is 
added to the pyridinium salt (2.23), to give an unstable dihydropyridine 
which, on immediate reduction, affords the tetrahydropyridine(2.24).
Acid catalysed cyclisation yields the benzomorphan (2.25). The 










(2) 45% HBr 
in HOAc




1,3,4-trialkylpyridinium salt (2.23) to the tetrahydropyridine (2.26), 
which is then quaternised with an appropriate benzyl halide to give 
the tetrahydropyridinium salt (2.27). Rearrangement of (2.27) is 
effected with phenyl-lithium to give the tetrahydropyridine (2.24) 
which is cyclised in acid to the benzomorphan (2.25). The product(s) 
from the Steven's rearrangement, steps (2.27) (2.24), is dictated
by the stability of the ylide intermediate.
The Grewe route is highly versatile, as the nature and positions 
of the R groups can be varied. In fact, a wide variety of substituted 
benzomorphans have been prspared by this . r o u t e . 104^ Although 
the Grewe route is extremely useful, it suffers, in certain instances, 
from difficulties in preparing the required alkylpyridines.
There are several other routes for preparing benzomorphan structures 
with specific substitution which are not yet developed into generally 
useful methods .These include: piperidinol and related cyclisations^^^'^^^ 
Beckmann rearrangement reactions^^^, meta-bridging^^^ and straight­
forward modification of substituents on the benzomorphan ring by 
classical reactions, such as alkylation, acylations, etc.
Stereochemistry of 6 ,7-benzomorphans
From an examination of models, it may be demonstrated that the 
aminoethyl bridge in 6 ,7-benzomorphans must be cis-fused to the 
tetrahydronapthalene skeleton, the trans-isomer being too severely 
strained to be thermodynamically possible. Thus, the 5-substituent
37,
(2.9a) is in a trans-configuration to the 1,2-bond. However, the 




ring C of 2,5-dimethyl-6,7-benzomorphan (2.9a), introduces a new
stereochemical dimension. That is, an added cis-/trans-isomerism.
The stereochemistry of these substituents could be related to either
the hydroaromatic ring B , or the piperidine ring C . For example,
the Grewe synthesis of 2,5-9-trimethyl-6,7-benzomorphan (2.25a)and
(2.274)yields principally the product {2,26a) where the methyl groups
at C-5 and C-9 are cis- with respect to the hydroaromatic ring B,
{trans- with respect to the piperidine ring C) and designated by 
91May and Eddy as a . Small quantities of the minor isomer, designated 
, where C-5 and C-9 methyl groups are trans- with respect to the 
hydroaromatic ring (and cis- with respect to the piperidine ring) 
have also been isolated. Both methods of isomer designation will be 








2.3 Structure-Activity Relationships in 6 ,7-Benzomorphans'
Since the preparation of 2'-hydroxy-2,5-dimethyl-6,7-benzo­
morphan (R = OH, 2.9), by May and Murphy^^, much time and energy has 
been devoted to synthetic variation of the 6 ,7-benzomorphan nucleus. 
Analgesics showing separation of analgesic and physical dependence 
characteristics have been produced^^'^^'^^^, and many interesting 
if somewhat puzzling, structure-activity relationships revealed.
A brief review of the structure-activity relationships in the 6,7- 
benzomorphan series will now be presented, with emphasis on ring 
substituents and stereochemical aspects.
39.
2.3.1 A-ring modifications
The introduction of a phenolic hydroxyl group at the 2'- 
position of 6,7-benzomorphans yields compounds with enhanced analgesic 
potency and reduced toxicity compared to the unsubstituted analogues^^^'^^^ 











Acétylation of a benzomorphan 2'-hydroxyl group further increases 
analgesic potency: 2'-acetyl-2,5-dimethyl-6,7-benzomorphan (R =
OOCCH^, 2.9) compared with 2'-hydroxyl-2,5-dimethyl-6 ,7-benzomorphan 
(R = OH, 2.9). The replacement of either the 2'-H or 2'-hydroxyl 
group with nitro, amino or halo groups in 5,9-dialkyl-2-methyl-
6 ,7-benzomorpans (2.29) gave compounds with diminished analgesic 
potency and increased toxicity, as determined by the mouse hot plate 
test L12 (see Table 1) .
Me
1
a X = H, Y = R.
X = Rg, Y = H
(2.29)
40.
112Table 1. Comparison of analgesic activity of 2'-substituted
benzomorphans^
Entry 2 -methyl-6 ,7-benzomorphan ED5 0 (mg/kg) s.c.
1 a-5,9-Diethyl- 2.5
2 2 '-hydroxy- 2 . 1
3 2 '-nitro 9.4
4 2'-amino-(2 HBr) 18.7
5 6-5,9-Diethyl- 2 . 1
6 2 Vhydroxy- 0 . 2
7 2 '-nitro- 25.0
8 2'-amino- (2 HBr) 13.2
9 3-5,9-Dimethyl- (HBr) 2.5
1 0 2 '-hydroxy 0.3
1 1 2 '-nitro 1 1 . 1
1 2 a-5 ,9-Dimethyl- 13.5
13 2 '-hydroxy 1 . 2
14 2 '-chloro 47.0
15 2 '-fluoro 22.7
16 Morphine 1 . 2
a. All salts are HCl unless otherwise stated.
This reduction in activity is much more pronounced in the _B- than 
in the a-series (compare entries 1 - 3  and 5 - 7 ,  Table 1). The 
effects of substitution at the 3'-position of the aromatic ring has
41
\ 7 '





also been studied by Ziering et They found that 3'-methyl-
benzomorphan derivatives are weakly active in both the mouse hot 
plate and writhing tests, but, with appropriate nitrogen substituents 
are good antagonists. For example, N-cyclopropylmethyl analogue
(2.29) = >45 mg/kg; = 0.7 mg/kg body weight.
2.3.2 Structure-Activity relationships in compounds bearing B 
and C ring substituents
Following the successful preparation of 2'-hydroxyl-2 ,5-di­
me thy 1-6,7-benzomorphan, a series of 5-alkyl and 5,9-dialkyl (o-cis 
and .^-trans) derivatives of 2 '-hydroxyl-2 -methyl-6 ,7-benzomorphan 
have been synthesised and tested for analgesic activity in mice, and 
physical dependence capacity in monkeys^^' The results
are illustrated in Table 2. These show that the trans- (9_3)-isomers 
in the dialkyl homologues are generally more potent than the cis- 
(9o)-isomers (see Table 2; also Section 2.3.4).The same trend has
been observed for 9â  and 9^ analogues of 2 '-hydroxy-2 -methyl-6 ,7-
118benzomorphan lacking a quaternary carbon at C- 5 . For example,
the 9B analogue (2.30b), of isomeric 2 ,9-dimethyl-2'-hydroxy-6 ,7- 
benzomorphan was 4 times as potent as the 9o-analogue (2.30a) in the 





ED 4.3 mg/kg 50
(2.30b)
ED^q 1 . 1  mg/kg
43
Table 2. 114 Pharmacology of (±)-5-alkyl and (±)-5,9-dialkyl-2-methyl-
6,7-benzomorphans.
CH
-5-Monoalkyl and o-6,9-dialkyl 
compounds
OH







1 Me H 10.4 175 2-60, no suppression None
2 Et H 2.3 170 1-16, " Low
3 Pr H 2.1 130 3-30, " None
4 Me Me 3.0 175 24, Low
5 Me Et 1.5 134 2-12, " None
6 Et Me 4.9 309 740, Low
7 Et Et 4.2 425 2-60, "
8 Pr Me 2.9 7300
9 Pr Pr 71.2 7 4 0 0 3-48, " None
/ C H
OH
^ - 5,9-Dialkyl compounds
10 Me Me 0.44 67
11 Me Et 0.47 100
12 Et Me 0.27 75
13 Et Et 0.28 120
14 Pr Pr 0.87 55








Footnote: a. Expressed in mg/kg(mice, subcutaneous administration)
b. All abstinence signs were not uniformly expressed by 
any dose (to 12 mg/kg) which did not produce some 
side effects.
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The cis-compounds in the 5,9-dialkyl, and other 5-monoalkyl,derivatives 
in the benzomorphan series have little or no ability to substitute 
for morphine in addicted monkeys. Of the monoalkyl compounds 
(entries 1-3, Table 2) it can be seen that the 5-ethyl and propyl 
analogues possess similar levels of analgesic potency which is some 
4 to 5 times greater than the 5-methyl compounds. In the o-dialkyl 
series, maximum activity was shown by the 5-methyl-9-ethyl derivative 
(entry 5, Table 2), while the 5-ethyl-9-methyl (entry 12, Table 2) 
proved to be the most effective in the g-series.
Other 5-substituted benzomorphans have been prepared. 9-methyl-
5-pheny1-6,7-benzomorphan (2.31), prepared by Clarke et al. gave
only the 9^-isomer, which is equipotent with ^-metazocine (entry 1 0 ,




122construction of prodine-like benzomorphans (2.32)
45







The author will now briefly consider those 5-alkyl and 5,9-
dialkyl benzomorphans additionally substituted in position 9. C-9
hydroxylation of 6,7-benzomorphans, a situation comparable to 14-
hydroxylation of morphines and morphinans, leads to a decrease in
124analgesic activity in the N-Me compounds. (See Table 3)
Compare the corresponding values in Table 2.
Similar C-9 hydroxylation of benzomorphans bearing antagonist
side chain leads to an increase in antagonist activity, in particular,
9_3“hydroxylation. For example, 96-hydroxypentazocine is 3 times
125more active than pentazocine as an antagonist of pethidine 
Janssen^^^ reported the effect of the introduction of a second 
methyl group in the 9a-monomethyl benzomorphan derivatives displaying 
agonist and antagonist activity. The 9,9-dialkyl compounds(2.34) 
produced are pharmacologically similar, and more potent and longer 
acting, than the parent compounds.
124Table 3. Analgesic activity of 9-hydroxy-6,7-benzomorphans
CH
a-9-OH-6,7-benzomorphans






































Attention is now given to those benzomorphans with alkyl sub­
stituents in positions 5 and 9 which also bear a C-8 substituent.
The introduction of an oxygen function on the benzylic carbon at C-8
of benzomorphan produces another subseries displaying a varied mix
127of agonist and antagonist properties . Essentially, carbonyl 
oxygen at C-8 greatly reduces narcotic antagonist activity, while 
agonist activity remains unchanged. For example, 8-oxocyclazocine 
(2.35) is a potent agonist in acetylcholine-induced writhing tests, 
but a weak antagonist of pethidine (compare both agonist and anta­
gonist activities of cyclazocine, = 0.15 mg/kg; AD^^ = 0.02 mg/kg)





8 -Hydroxy-benzomorphans have also been reported, all of which
127 128are of low potency either as agonist or antagonist ' . For
example, 8 -hydroxycyclazocine (2.36). (ED^^ = 10 mg/kg; =
1 1  mg/kg).
(2.36)
Finally, 5-alkylbenzomorphans additionally substituted in posi­
tions 3 and 4 have also received some attention. 3- and 4-Methyl
benzomorphans (2.37) and (2.33) respectively have been synthesised






= 11.9 mg/kg s.c. = 4.2 mg/kg s.c
49.
The lower agonist potency (mouse hot plate) of the 3-methyl derivative
compared with the 4-methyl analogue has been attributed to the
hindrance of the tertiary nitrogen in the former. Also, the higher
agonist potency of the 4,5-dimethylbenzomorphan (2.35) compared with
the 5,9-positional isomer (ED^^ = 4.5 mg/kg) suggests that the usual
positions of dialkyl substitution in the piperidine ring of 6,7-
benzomorphan (positions 5 and 9, relating it to the morphinans)
129may not be optimal regarding activity
Homobenzomorphans
Amongst skeletally modified 6,7-benzomorphans, ring C expanded
analogues (homobenzomorphans) of type (2.39) and (2.40) are most
prominent. Compounds of the former type with significant agonist^^^





have been described. Of the latter type, the most potent derivative 
was (2.40, = Rg = CH^, R^ = H) which had a tail flick in mice
slightly lower than that of morphine (see Table 4) 130
50.
Table 4. Analgesic activity of some homobenzomorphan {2.40)
130derivatives
Entry ED_^ s.c. LD__50 50
ymole/kg ymole/kg
1 *1 = *2 = *3 = G 10.7 1 2 1
2
b= R^= H; R^ = Me 9.9 184
3 bR^ = R^ = H; R^ = Me 8 . 0 153
4 R^ = Me; ^2 ~ ^3 ~ 7.0 67
5 bR^ = H; R^ = R^ = Me 5.2 126
6 R^ = H; R^ = Rg = Me^ 4.1 113
7 cMorphine 4.4
8 Codeine^ 30.7
a) Administered as lactate in saline
b) Administered as HBr in saline
c) Administered as HCl in saline
d) Administered as phosphate in saline
2.3.3 Some structure-activity considerations of benzomorphans 
bearing different nitrogen substituents
The replacement of the iV-methyl group of 6,7-benzomorphans 
leads to both quantitative and qualitative changes in the structure- 
activity relationships. It is, however, pertinent to point out that 
the need for either //-methyl or other conventional agonist/antagonist 
N-substituents is not exactly critical for activity. Analgesic 
activity has been found in compounds such as {2.41) with a secondary 





In addition, the 2 amine of the 8_8“hydroxy-6 ,7-benzomorphan 
(2.42; R = H) has been shown to have analgesic activity about half 
that of codeine in the mouse hot plate test, while the corresponding 
N-methyl analogue was inactive^^^.
R = H, = 13.7 mg/kg
R = Me, Inactive
Codeine HCl, = 7.5 mg/kg
OH
(.2.42)
A Study with a series of cis-W-alkyl-2'-hydroxy-5,9-dimethyl-2- 
desmethy1-6,7-benzomorphan (2.43) has revealed that there is a 
complete loss of activity when the methyl group on the nitrogen of
52
2'-hydroxy-5,9-dimethyl-6,7-benzomorphan (entry 1, Table 5) is 
replaced by ethyl, propyl or butyl, but is restored when the group 
on nitrogen becomes amyl^^^'^^^. (Table 5).
-Me,
OH
(ED^^= 0 . 2 0  mg/kg)
b) R = -CH2 -CH=CMe2  
(AD^Q=3.9 mg/kg)
c) R = -CHg-C-CjH^
{2.43) (AD^^=0.02 mg/kg)
However, the N-propyl compound (entry 3, Table 5) is one of the
most potent morphine antagonists known (AD^^ = 0.019 mg/kg, cf.
Nalorphine 0.13 mg/kg)
Table 5. Analgesic activity of some a-
1356,7-benzomorphans (2.43)
2 -alkyl-2 '-hydroxy-5,9-dimethyl-









Replacement of the N-methyl of 2'-hydroxy-5,9-dimethyl-6,7-benzomorphan
with an W-phenethyl group gave phenazocine (2.43a) which is a potent
agonist, effective both orally and parenterally, with less abuse
potential than morphine^^'^^^. Similar replacement with classical
antagonist substituents such as dimethy]allyl and cyclopropyl-
methyl gave pentazocine (2.43b) and cyclazocine (2.43c) respectively.
The former, though a weak antagonist, is the first narcotic antagonist
138analgetic to be used in man , and the latter is a potent narcotic
139antagonist and analgetic
More recently, a new gradation of antagonist to agonist properties
in benzomorphans has been obtained by various N-furylalkyl sub- 
140stituents . The 2-arylethyl derivative 2.44a is a potent analgesic
R/
OH
a: R = ,o
b: R = -CHgo
141(30x morphine) , while the lower homologue (2.44b) has only feeble 
analgesic properties but is as potent an antagonist as nalorphine. 
The activity profile of (2.44b) may be varied by structural modif­
ications, illustrated in Table 6 .
54,





Analgesic^ none + ++ +++
a) 50% suppression of morphine analgesic in mice by the tail clip 
test.
b) Tail-clip, hot plate and writhing tests in mice.
In sharp contrast, the N-tetrahydrofuryl benzomorphan (2.45), saturated




NTsubstituted benzomorphans as receptor probes
Several benzomorphan derivatives with specific N-substituents, 
are used as receptor probes. Examples include the W-2-hydroxyalkyl
55.
and N-2-bromoalkyl compounds prepared by May et al. for their 
capacity to irreversibly interact with narcotic analgesic receptors.
143None of the compounds produced showed any marked lopg-lasting activity
Another example is N - (2,4,5-trihydroxyphenylethyl)-normetazocine
144(2.46) prepared by Rice et al. in an attempt to deliver a 6 - 
hydroxyldopamine-like alkylating moiety to the analgesic receptor.






blastoma x glioma cells).
From the examples presented above# it is clear that agonist 
or antagonist activity is not.limited to the classical //-substituent 
such as N-CHg, N-allyl or N-CH^^C-C^H^ or even to the tertiary 
amine as previously believed. It is now thought that the overall 
structure and geometry of a particular compound has an overriding 
effect concerning the ratio of agonist and antagonist activity.
2.3.4 Stereochemical Aspects
As with other classes of potent analgesics with asymmetric 
centres, the influence of molecular geometry on the analgesic response
56,
of 6,7-benzomorphans has been clearly demonstrated. The effects 
are not only seen with enantiomeric pairs (i.e. molecules related 
as object to mirror image), but also with diastereoisomers (stereo­
isomers with more than one asymmetric centre that are not related 
as object to mirror image), although the potency variations in 
the latter are usually less extreme than in the former. It has been 
shown, for example, that in a series of 5,9-dialkyl-2'-hydroxy-2- 
methyl-6 ,7-benzomorphans (Section 2.3.2), the 9^-(trans) isomers 
are always more potent than the 9a-(cis-) isomers. The cis-isomers 
have little or no ability to substitute for morphine in addicted
monkeys, whereas the trans- isomer does suppress withdrawal symptoms
95in addicted monkeys
May and Eddy, have resolved cis-5,9-diethyl-2'-hydroxyl-2-methyl-
6 ,7-benzomorphan (2.47), and demonstrated a stereospecific separation
between analgesic activity (as measured by the hot plate technique)
109and addiction liability, as assessed in the monkey . The laevo- 





as the racemate in the mouse hdt plate. It precipitated withdrawal
in addicted monkeys and displayed analgesic antagonist properties
145in the rat tail-flick test . On the other hand, the dextrorotatory
57
isomer (+) had 1/lOth the analgesic activity of the antipode and 
showed physical dependence capacity in monkeys. The low physical 
dependence of the racemate (2.47) is attributed to antagonism between 
the two antipodes because of the antagonist activity shown by the 
(-) isomer. This same trend was observed when 5-phenyl-9-methyl
and 5-propyi-9-methylbenzomorphan derivatives were resolved and
 ̂ . ^146tested
However, the reports that strong analgesic activity and narcotic
antagonism are found in the laevo forms of benzomorphans and weak.
analgesic and physical dependence capacity in the dextro forms
has not proved to be a general principle. For example, both optical
isomers of (2.46), lacking a quaternary carbon, were analgesics
with no physical dependence capacity, and both showed antagonist 






From the structure-activity relationships treatise in the 
preceeding sections, the fundamental structural features associated 
with analgesic activity in the 6,7-benzomorphans seem to be the 
presence of an aromatic ring bonded to a saturated two or three carbon 
chain, terminating with an amino nitrogen. To be more specific, 
the presence of an appropriately positioned phenolic hydroxyl, 
tertiary amino functionality and a quaternary carbon appear to enhance 
analgesic activity in most cases. In addition, the delicate balance 
between the influence of ring substituents, N-substituents and 
stereochemical factors in determining the nature and level of 
activity of any particular benzomorphan has been highlighted.
59,
2.4 Aims and Objectives of the present work
The lower analgesic agonist potency in the mouse hot-plate test 
of cis-2 ,3,5-trimethy1 -6 ,7-benzomorphan when compared with that of 
the trans-2,4 ,5-trimethyl isomer has been attributed tentatively 
to the occurrence of hindrance of the nitrogen lone pair in the 
former, and this led to the proposal by Parfitt and Walters that 
hindrance of the tertiary nitrogen lone pair in morphine-like anal­
gesics may have some bearing on both the level and type of analgesic 
activity exhibited. One of the aims of this thesis is to investigate 
further the possible non-bonding electron involvement in analgesic 
activity by obtaining data on:
i) 3-monosubstituted-6,7-benzomorphans
and ii) 3 ,3-disubstituted-6,7-benzomorphans
The main objectives were to assess the contribution of the effect on 
molecular geometry of the orientation of the 3-alkyl group, and also 
to impose conformational constraints on the nitrogen lone pair in the 
3,3-disubstituted compounds in the hope that any change in activity 
may throw some light on its role in receptor binding.
In addition, it was considered desirable to obtain phenolic 
analogues of the 3- and 4-methyl-6,7-benzomorphans, since a phenolic 
group enhances activity in benzomorphans generally and to secure 
data which complements those on the 9-methyl analogues.
Finally, novel W-amidinobenzomorphans in the a-5,9-dimethyl 
derivatives were prepared. The objective here was to observe the 
effects on analgesic activity of
60.
i) an increase in the basicity of the nitrogen centre
and ii) a shift of the positive charge centre from nitrogen to
carbon.
The work in this thesis therefore entailed; 
i) Syntheses







The Syntheses and Structure-Activity 














(1) 47% aq HBr
(11)45% HBr In HOAc
H (3 .5 ) = CH^, Rg = H




3.1 3-Substituted-6 ̂ V-benzomorphans
The syntheses of 6 ,7-benzomorphans for use in subsequent reactions 
are first discussed.
2,3,5-Trimethyl-6,7-benzomorphan was synthesized by the Grewe 
route as illustrated in Scheme 5. Thin layer chromatography (TLC) 
and proton magnetic resonance (^H n.m.r.) of the crude cyclisation
129product showed two isomers. An earlier report by Parfitt and Walters 
described only a single isomer. The major isomer, (±)cis-2,3,5-tri­
methyl - 6  , 7 -benzomorphan (3.5), was isolated as the hydrochloride and 
the minor isomer, (±)trans -2,3,5-trimethyl-6,7-benzomorphan (3.6), 
as the oxalate salt. N.m.r. examination of the two isomers re­
vealed differences in both the 3-CH^ and N-CH^ chemical shifts (see 
Table 7). The cis isomer (3.5) showed a 3-CH^ doublet resonance at
60.92 ppm, and the trans-isomer a doublet at 0.44 ppm. Examination
148of Dreiding models and the Bovey-Johnson shielding map showed 
that if the piperidine ring is in the more favourable chair form, 
the 3-CH^ protons in the trans-isomer (3.6) would lie. within the 
aromatic diamagnetic shielding zone. Hence, the high field absorption 
of the 3-CH^ protons in the trans-isomer. The N-methyl proton 
resonance in the cis-isomer is slightly upfield of that in the trans 
isomer. In addition, the hydrochlorides of (3.5) and (3.6) exhibit 
epimerism about nitrogen, as is evident by the duplication of N-Me 
and other signals in the ^H n.m.r. studies (Table 7, entries 3 and 4 ;p.8 6 ) 
Similar observations have been made for isomeric 4-phenyl-piperidines 

















2,5,9-Trimethyl-6,7-benzomorphan was synthesized using Fry's 
method^^ (see Scheme 6 ). The cyclised product gave exclusively 
0 -2 ,5,9-trimethyl-6,7-benzomorphan (3.11) , as deduced from inspection 
of the base n.m.r. spectrum. This spectrum showed a C-9 methyl 
doublet resonance at 60.83 ppm (J = 6  Hz) and no resonance at 1.24 ppm 
due to the g-isomer.
3.1.1 3-Substituted-2,3,5-trimethyl-6,7-benzomorphans
The difficulties in obtaining the required alkyl pyridine 
starting materials precluded the use of the Grewe synthesis for this 
series of compounds. Therefore, other possible methods of introducing 
a carbon-carbon bond (C-C) at the 3-position of 2,3,5-trimethyl-6,7- 
benzomorphan were considered. The functionalisation of the 3-position 
of (3.5) in advance by converting (3.5) to intermediates such as the 
cyclic iminium ion (3.12), or the 3-cyanoamine (3.13) appeared to 






(3.13 , partial structure)
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Use was made of the fact that iminium ions show properties similar 
to carbonyl compounds and can be thought of as a resonance hybrid 
of two similar charged forms (3.14 and 3.25). They therefore function
/ " \
0.14) (3.15)
as electrophiles, adding nucelophiles such as cyanide ion, lithium 
alkyls, -hydrides and Grignard reagents to form substituted amines. 
Iminium ions are readily available from C-protonation of the corre­
sponding enamines,which are obtained by the oxidation of amines by 
various reagents, particularly mercury (II) acetate. Oxidation of 
cyclic amines with mercury (II) acetate gives the corresponding 
enamines^^^. This reaction has been applied to pethidine^^^, 
oripavines^^^ and certain alkaloids^^^'^^^ but failed with morphine 
and c o d e i n e . O t h e r  oxidative methods utilising benzoyl peroxide^^^, 
manganese dioxide^^^ and electrochemical methods^^^ have been reported.
Mercury (II) acetate oxidation of both isomers of 2,3,5-trimethyl-
6 ,7-benzomorphan (3.5 and 3.6) gave A3'%dehydro-2,3,5-trimethyl-6,7- 
benzomorphan, isolated as the iminium perchlorate (3.17). The proposed 
mechanism^^^' for mercury (II) acetate oxidation requires the 
formation of an intermediate mercurated complex (3.26) with nitrogen 












o^-hydrogen and cleavage of the mercury-nitrogen bond. This four- 
centre elimination implies that the hydrogen to be eliminated should 
have a trans- relationship with the lone pair of electrons on 
nitrogen, or be capable of attaining trans-coplanarity with the W-Hg 
bond in the mercurated complex (if not sterically hindered) . 
Indications that a trans-coplanar relation was necessary are found
68,
in the result of studies of mercury (II) acetate oxidation of
alkaloids. For example, yohimbine {3.18) is readily oxidised at







Additional evidence is provided by the mercury (II) acetate oxidation 
of 11-methyl-ll-azabicyclo (5,3,1) hendecane (3.20), a tertiary 
amine where the hydrogens on the equivalent o-tert carbons are 
sterically prevented from attaining trans-coplanarity with N-Hg 
bond in the mercurated complex. The product is the N-demethylated
69,
analogue (3.21) resulting from abstraction of one of the protons 
of the N-methyl group which has virtually unrestricted rotation and
can be aligned readily in the steric relationship favourable for




From the above requirements, and assuming a chair conformation of 
the piperidine ring of 2,3,5-trimethyl-6,7-benzomorphan, the formation 
of the iminium salt (3.17) from the trans-isomer (3.6) seems 
anomalous as it apparently does not possess any a-hydrogen trans- 
to the nitrogen lone pair, except those in the #-methyl group.
The absence of any N-demethylated material in the product excludes 
the elimination of one of the #-methyl protons and the loss of the 
other proton at C-1 would contravene Bredt's rule. However, the 
ability of (3.6) to form salts epimeric about nitrogen (see p.63) 
together with the apparent lack of conformational preference of 
reactive mercury species, for example HgBr^^^ and HgCl^^^, makes 
the formation of N-mercuriacetate epimeric about nitrogen a possi­
bility. Inspection of a model of (3.6) revealed that the equatorial 
proton at C-3 is capable of trans-coplanarity with an equatorial
70.
N-Eg bond in a twist conformation of the piperidine ring. Therefore, 
trans- coplanar elimination of this proton could lead to the same
M e
(3.16, partial formula)
iminium salt (3.17) as the one obtained from the cis-isomer and,
consequently, may explain this anomaly. It is pertinent, however,
to point out that there are different schools of thought on the
conformational preference of the acetoxymercuric group (HgOAc),
164for example, on cyclohexane. Previous work by Jensen et al. 
concluded that the acetoxymercuri group has no conformational pre­
ference but, more recently, Anet and Krane^^^, using high field 
(59 Kgauss) and n.m.r., have reported that the HgOAc group 
exists preferentially in the axial form on cyclohexane. Given close 
parallels in conformation cyclohexane and piperidine rings, our work 
seems to agree with the findings of Jensen et al.
The structure of the iminium salt (3.17) was confirmed by 
the carbon-13 nuclear magnetic resonance (^^C n.m.r.) chemical shift
of the C-3 carbon at 6188.09 ppm (Table 11, p. 110 ) and a
\  + -1corresponding C = N band at 1680 cm in the infra-red (i.r.)

























n.m.r. resonance relative to corresponding values in 3.5 (Table 7). 
Positive ion fast atom bombardment mass spectroscopy (+ve ion FAB) 
gave the (M+1) parent ion at m/z 214.06 (100%) (Fig. 1) and electron 
iicpact (El) mass spectrometry gave the due to the enamine (3.22) 
at m/z 213.12 (34.13%). Other diagnostic peaks (El) are at m/z
198.05 (19.4%), due to loss of the C-5 angular methyl group, and 
122.03 (27.8%) due to the loss of the 1,2,4-trimethyl pyridinium 
ion (Scheme 7). The base peak was observed at m/z 71.
3-Cyano-2,3,5-trimethyl-6,7-benzomorphans
An earlier method^^^' of a-cyanation of tertiary amines in­
volves the aqueous cyanide treatment of the iminium salt from mercury 
(II) acetate oxidation. More recently, Portoghese^^^ described a mild 
method of o^-cyanation in good yields, of a series of compounds re­
lated to morphine. The process involves the oxidation of the amine 
with hydrogen peroxide, estérification of the resultant N-oxide with 
trifluoroacetic anhydride and subsequent treatment with aqueous 
potassium cyanide. Both methods are employed in the present work.
Aqueous potassium cyanide treatment of the iminium salt (3.17) 
afforded 3-cyano-2,3,5-trimethyl-6,7-benzomorphan (3.26).
The structure of the 3-cyanoamine (3.26) was confirmed by -C=N i.r.
-1 13absorption at 2225 cm and the corresponding C n.m.r. shift at
6119.5 ppm. In the n.m.r. spectrum, the 3-CH^ protons resonated
downfield at 1.37 ppm as the expected singlet, compared to the
3-CH^ protons of the unsubstituted base (entries 1 and 6, Table 7) .
The configuration of the 3-cyano group was assigned as axial from a
73.
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Figure 1. FAB mass spectr-am of iminium perchlorate (3.17) 





consideration of other and n.m.r. data.
Lithium aluminium hydride reduction of (3.26) gave a 50:50 
mixture of cis and trans -2,3,5-trimethyl-6,7-benzomorphan. In 
this reaction, lithium aluminium hydride substitutes at C-3 
rather than reduce the nitrile group, and the reaction would be 
SN^ judging from the formation of an almost equal mixture of
isomers from a single 3-cyano isomer. Similar reactions have
^ , 152,174been reported previously
When Portoghese's method^^^ (a modified Polonovski reaction) 
was employed, o-cyanation of (3.5) proceeded readily to afford the 
expected 3-cyano-3-methyl-6,7-benzomorphan (3.26) in 67% yield, 
identical to the mercury (II) acetate/potassium cyanide product. 
However, the axial C-3 methyl substrate (3.6) gave 2-cyanomethyl-
3,5-dimethy1-6,7-benzomorphan (3.29) in 60% yield (see Scheme 8).
This seems anomalous considering that the two isomers gave the same 
product in the mercuric acetate oxidation. During the Portoghese 














to involve a ^-trans-elimination of the trifluoroacetoxyammonium 
ester (3.27) to afford, normally, the endocyclic iminium salt 
(3.5 ^.27, = C H ^ — ►3.17). The stereochemistry of 1-alkyl-
piperidine quaternisations^^^'and #-oxidation^^^'^^^ has been 
demonstrated to occur largely from equatorial N-alkyl conformers 
where the entering group is preferentially axial and this is likely 
to be the case with 2-methyl benzomorphans. However, where the 3-methyl 
group is axial, the trifluoroacetate ester cannot give an endocyclic 
iminium salt via a trans-^-éliminâtion, because the hydrogen at the 
3-position is not trans-coplanar to the trifluoroacetoxy group on 
nitrogen. Elimination occurs from the N-CE^ group to afford an inter­
mediate exocyclic iminium salt (3.26) to which Q-I adds readily.
The 2-cyanomethyl-3,5-dimethyl-benzomorphan (3.29) was characterised 
from its and n.m.r. data. The n.m.r. spectrum showed a
distinct downfield shift of the 2 -position methylene group, appearing 
as a 2h singlet at 63.48, with the corresponding signal observed 
at 636.41 ppm. (entry 20, Table 11). The appearance of the 3-CH^ 
group as a doublet distinguishes (3.29) frctn the 3-cyano-2,3,5-tri- 
methyl-6 ,7-benzomorphan (3.26) where the 3-CH^ appeared as a singlet 
(compare entries 6  and 7, Table 7).
Lithium aluminium hydride reduction of (3.29) to the ethylene- 
diamine derivative (3.30), which was isolated as its oxalate salt, 
added support to the structural assignment. The ethylenediamine 
methylene groups of (3.30) appeared as an apparent 4H singlet at 
62.76 ppm in the n.m.r. spectrum (Table 7, entry 8 ) with the 
corresponding shifts at 654.34 and 39.82 ppm, data comparable to
analogous shifts of C-1 and C-3 of N-methylethylenediamine^^^'^
77
N - CH - CH - NH2/ 2 2 2
CH^ 55.1 41.9
3-Alkyl-2,3,5-trimethyl-6,7-benzomorphans
Simple iminium salts have been shown to react with organo-
metallic reagents to give C-alkylated derivatives, and various
172 173Grignard reagents have been employed ' (see Scheme 9 for 
general reaction)
R MgXN =  C
SCHEME 9
The introduction of a second alkyl group at the 3-pcGition of 2,3,5-
trimethyl-6 ,7-benzomorphan was achieved by reacting the cyclic iminium
salt (3.17) with methyl, benzyl and allyl-magnesium halides
(Scheme 10). Both allyl and benzyl magnesium halides gave the
expected C-3 alkylated products while no alkylated product could be
isolated with the methyl Grignard. A similar trend was observed during
1 (2)the reaction of methyl and benzyl magnesium halides with A ' -1,2,6-
trimethyl piperidinium perchlorate, when the yield from the former was 
174very poor . The greater reactivity of the benzyl and allyl Grignards 
can be attributed to the greater stability of the carbanion formed 










(3.31) = CH^, Rg = -CHgPh
(3.32) = -CH^-Ph, R^ = CH^
(3.33) R = CH^, R_ = -CH_-CH=CH,
(3.34) R^ = -CH2CH=CH2, R^ = CH^
SCHEME 10
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The product from the reaction of (3.17) with methylmaignesium 
iodide (Scheme 10) was an oil which darkened on exposure to air.
N.m.r. analysis of the crude product revealed a pair of doublets 
at 60.40 and 0.90 ppm attributable to both cis and trans-2,3,5- 
trimethyl-6 ,7-benzomorphan, and additional resonances indicated 
further components. The observed colour change could be due to 
the presence of enamine which would display instability to air. Any 
such enamine present could arise from basification of any unreacted 
iminium salt during the work up procedure. The appearance of signals 
due to cis and trans-2,3,5-trimethyl-5,7-benzomorphan (3.5 and 3.6) 
implies that méthylmagnésium iodide has caused some reduction of 
the iminium salt to the saturated amine. Although similar observation 
have been made in the reaction of tert.-butyl-4-N,W-dimethylcyclohexyl 
iminium perchlorate with a Grignard reagent having a hydrogen atom 
on carbon 2 (Scheme 11)^^^, it is unclear how méthylmagnésium iodide, 
lacking such structural property, could effect such a reduction.
3- Benzyl-2,3,5-trimethyl-6 ,7-benzomorphan
Benzyl magnesium chloride reacted readily with (3.17) to 
produce the two possible isomers of 3-benzyl-2,3,5 -tr imethyl-6 ,7- 
benzomorphan. Evidence for this came from TLC and n.m.r. analysis 
of the crude product. The major isomer (3.32) was separated by 
passage through a chromatographic column of silica gel, but attempts 
to obtain the minor isomer (3.37) were unsuccessful. The major isomer 
(3.32) was shown to have a trans-3-Me/5-Me configuration, on the 
basis of its 3-methyl proton shift (near 60.38 ppm (s) ) which implies 











the aromatic ring of the benzomorphan nucleus. N.m.r. analysis
was consistent with the structure and further evidence for the assign­
ment is discussed in Chapter 4 (p. 127 ) .
3-Allyl-2,3^5-trimethyl-6 ,7-benzomorphan
The two possible isomers of 3-allyl-2,3,5- trimethyl-6 ,7-benzo- 
morphan were obtained, evidence being secured from TLC and n.m.r. 
analysis of the crude base. The isomers were separated by column 
chromatography on silica. The major isomer (3.33) has a cis 3-Me/5-Me 
configuration, while the minor isomer (3.34) has a trans 3-Me/5-Me 
configuration (see Chapter 4, p. 127 ) . The axial orientation of the
81 ,
3-allyl group in (3.33) is substantiated by the vinylic chemical 
shifts which are to higher field than those of (3.34) due to aromatic 
shielding (footnotes e and f, Table 7).
The displacement of the cyano group of an o-aminonitrile, for 
example, (3.26), by Grignard reagent or lithium alkyls also offer 
a route to C-3 disubstituted compounds. Although an o-aminonitrile 
and a Grignard reagent may interact in one of 3 ways (see Scheme 12), 
a-aminonitriles derived from piperidine undergo nitrile displacement
(I) readily176 Indeed, precedents abound for the replacement of
a-cyano groijps in such an environment by alkyl groups of the Grignard 
or alkyllithium type^^^'^^^.








(1 0 % yield) (3..31) \  = CH3 , ^ 2 — --CH^Ph
(3..32) -CH2 Ph, = CH3
(3..33)
^ 1  = CH3 , * 2 =  .-CH CH=CH
(3,.34) -CH2 -CH==CH,2 ' ^ 2  = “ 3
SCHEME 13
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The reaction of (3.26) with methyllithium gave a mixture of 
about 10% 2,3,3,5-tetramethyl-6,7-benzomorphan (3.35) and 90% of 
(3.26), under all attempted conditions (Scheme 13). It proved 
impossible to isolate (3.35) in pure form. N.m.r. analysis 
of the crude product, however, showed singlets due to the C-3 methyl 
groups at 60.32 and 1.05 ppm. The products from the reaction with 
benzyl and allyl magnesium halides (Scheme 13) show the same spectral 
characteristics as those from the reaction with iminium perchlorate.
3.1.2 3-Substituted-2,5,9-trimethyl-6,7-benzomorphan
o-Cyanation of 2,5,9-trimethyl-6,7-benzomorphan (3.11) using 








The i.r. spectrum of (3.36) showed the expected -CËN band at
“1 132220 cm and the corresponding carbon shift ( C n.m.r.) at 119.62
ppm. N.m.r. (100 and 220 mHz), n.m.r., and lanthanide
shift reagent studies showed the orientation of the 3-cyano group
to be equatorial in the major product. Full evidence for this
assignment will be discussed in Chapter 4 (see p. 118 ) . The
84,
4 €.
lithium aluminium R eduction, product of 3-cyano-2,5,9-trimethyl-6,7- 





The reaction of 3-cyano-2,5,9-trimethyl-6,7-benzomorphan (3.36) 
with methyl, ethyl, benzyl and phenethyl magnesium halides afforded 
the axial 3-alkyl derivatives as the major products (Scheme 14), 
although traces of the minor (equatorial alkyl) isomer were always 
detected in the crude product. The full and n.m.r. evidence 
to support these assignments will be discussed in Chapter 4 (see 
p.118). Attempts to obtain the 3-allyl-2,5,9-trimethyl-6,7-benzo­
morphan were unsuccessful.
85.
Footnotes to Table 7
a. values in ppm from TMS
b. DMSO as solvent, TMS as standard
c. The N-methylene group resonates at 63,48 ppm, 
as a singlet
d. Both ethylenediamine methylene protons resonate 
at 62.76 ppm, as a singlet
e. 3-Allyl resonances (ppm): -CH=CE^- multiplet at 5.20,
and the vinylic methylene at 4.06 and 4.64.
f. 3-Allyl resonances (ppm): -CH=CE^~ multiplet at 5.80,
and the vinylic methylene at 5.04 (s) and 4.90.





shifts of some 6 ,7-benzomorphan derivatives in
Entries Compound N-Me 3-Me 5-Me 9-Me
1 3.5 2.40 0.90(d)
(J=6Hz )
1.36 -
2 3.6 2.43 0.42(d)
(J=6 Hz)
1.32 -
3 3.5 HCl^ 2.84 1 .0 2 ,1 . 2 0
(d)
1.44 -
4 3.6 HCl^ 2.74,3. 02(d) 0.52,0.88 
(J=71Iz)
1.32,1.44 -
5 3.17 3.65 2 .34(s) 1.52 -
6 3.26 2.52 1.37(s) 1.32 -
7 3.29 c 0.69(d)
(J=7Hz)
1.32 -
8 3.30 d 0.34(d) 1.32 -
9 3.32 2.56 0.38(s) 1.24 -
1 0 3.33 ^ 2.48 1.06 (s) 1.32 -
1 1 3.34^ 2.38 0.31(s) 1.32 -
1 2 3.11 2.40 - 1.36 0.83
(J=6 H2
13 3.36 2.58 - 1.38 0.84
14 3.37 2.3 - 1.36 0.83
15 3.38 2.49 0.42 1.32 0.84
16 3.39 2.50 g 1.29 0.80
17 3.40 2.64 - 1.23 0.81










(3..38) R = CH3
(3,.39) R = CK2 CH3
(3..40) R = CH^ -Ph
(3,.41) R = CH^CH^Ph
2'-Hydroxy-2,5,dimethyl-6 ,7-benzomorphan (3.45) was synthesised 
by the Grewe route as described by May and Murphy (Scheme 15) .
The structure was established by ^H and n.m.r. studies and
comparison of physical constants with literature values15
2 '-Hydroxy-2,3 ,5-trimethyl-6 ,7 -benzomorphan (3.46) was similarly
prepared by the Grewe route as in Scheme 15 (R = CH^) . The H n.m.r 













(3.45) R = H
(3.46) R = -CH^
SCHEIffi 15
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ci5  and trans-isomers in a ratio of about 5:1 respectively. The 
major isomer, cis-2'-hydroxy-6 ,7-benzomorphan (3.47), was obtained 
as a precipitate after washing the crude oil obtained from cyclisation 
with ether, but attempts to isolate a pure sample of the minor 
isomer (3.46) from the residue were unsuccessful. The n.m.r. 
spectrum of pure (3.47) was similar to that of the cis-isomer of
H p
(3.47) = CH^, R.2 = H
(3.46) = H, R^ = CH^
the non-phenolic analogue (3.5). This compound displayed a ^-CH^ 
resonance, as a doublet, at 60.93 ppm (entry 2, Table 8 ) and the 
corresponding chemical shift was observed at 20.53 ppm. In 
this and other phenolic benzomorphan analogues prepared, a general 
upfield shift of the aromatic protons in the n.m.r. spectrum 
and a distinct downfield shift in the n.m.r. spectrum of the 
2 '-aromatic carbon, with an associated upfield shift of both C-1' 






















Table 8 . chemical 
in DMSO*
shifts of sane 2’-OH- 6 ,7-benzomorphan derivative
Entry Compound N-Me 3-Me 4-Me 5-Me
1 3.45 2.24(s) - - 1.24(s)
2 3.47 2.26(s) 0.93 - 1.25(s)
(J=6 Hz)
3 3.49 - 0.83 - 1.24(s)
4 3.50 b 0 . 8 8 - 1.28(s)
5 3.51 c 0 .8 6 (d) - 1.28(s)
6 3.54 2.24(s) — 0.57(d) 1 .2 2 (s)
(J=6 Hz)
Footnotes to Table 8 .
a. Values in ppm from
b. The vinylic proton
TMS
resonances at about 5. 80 ppm (-CHg--CH) ,
4.96 - 5.36 ppm (-CH-CH^)
c. Cyclopropyl proton resonances at between 0.08 and 0 . 6 0  ppm.
Von Braun N-déméthylation of (3.47) gave 2'-hydroxy-3 ,5-di­
methyl-6 ,7-benzomorphan (3.49). Compound (3.49) was converted to the 
corresponding N-allyl compound (3.50) by direct alkylation with allyl 
bromide in ethanol, and to the W-cyclopropylmethyl derivative (3.51) 
by direct acylation with cyclopropylcarboxylic acid chloride and 
lithium aluminium hydride reduction of the amide intermediate.
Attempts to prepare the N-phenethyl analogue were unsuccessful (see 
Scheme 16). The ^-substituted compounds (3.50 and 3.51) were 
identified from and n.m.r. characteristics of the N-substituents 
The W-allyl compound (3.50) gave vinylic proton resonance at 65.00 ppm 







*1 = *2 = CH]
SCHErÆ 17
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field signals at 6138.04 ppm, due to the vinylic methyne carbon, and 
6115.38 ppm due to the vinylic methylene carbon.The N-cyclopropyl- 
methyl analogue showed high field multiplets between 0 . 0 8  and 0.60 
ppm in the n.m.r. spectrum due to the cyclopropyl group protons, 
and the associated chemical shifts in the n.m.r. spectrum at 
2.60, 5.90 and 9.97 ppm, corresponding to the methylene carbons and 
methyne carbon respectively.
4,5-dialkyl-6 ,7-benzomorphans
2'-Hydroxy-2,4,5-trimethyl-6 ,7-benzomorphan was prepared by the
129method described by Parfitt and Walters for the non-phenolic analogue, 
using p-methoxybenzyl magnesium chloride (Scheme 17). The product
(3.54) was exclusively that in which the C-4 methyl group is orientated 
equatorially, thereby lying in the shielding zone of the aromatic ring 
(Table 8 , entry 6 ). Other ^H and n.m.r. shift values for (3.54) 
are consistent with its structure.
3.3 Pharmacology and Structure-Activity Relationship Correlations
The lower analgesic potency of cis-2,3,5-trimethyl-6,7-benzo­
morphan hydrochloride (3.5 HCl) relative to that of trans-2,4,5-tri-
methyl isomer (3.55), (Table .9, entries 2 and 13), was attributed
129by Parfitt and Walters to possible hindrance of the nitrogen lone 
electron pair by the equatorial 3-methyl group of the former. This 
led to the suggestion that hindrance of the nitrogen lone electron 
pair may have some bearing on the type and level of analgesic activity 




nitrogen lone electron pair in opiate-receptor interactions.
179Among these, Belleau et al . in explaining the inactivity of 
7V-methyl-D-normorphinan (3.56a) and its 3-hydroxyl analogue (3.56b) 
(which are neither agonist nor antagonist) relative to that of 
morphinan (3.57) and benzomorphan ring system, have shown the critical 
importance of the relative orientation of nitrogen electron pair in 
productive interaction with the opiate receptor. The X-ray analysis
,CH 3 (3.56a) X = H 
{3.56b) X = OH
of the structures of (3.56a) hydrobromide and morphinan (3.57) re­
vealed that the lone pair of the former projects towards the benzene
ring; those of the latter and benzomorphan ring system project away 
frcxn the benzene ring.
95,
(3.56a) (3.57)
This led to Belleau's theory of "clastic binding", which proposed 
that the binding of drugs to opiate receptor involved an interaction 
of the nitrogen lone electron pair with an electrophilic site on the 
receptor, followed by a stereospecific electron transfer away from 
the ligand^^^. This view was endorsed by Kolb, who proposed a new 
opiate-receptor model in which only one conformation of the receptor, 
with two different specially fixed amine sites (one agonist and 
one antagonist), is needed for binding of both agonist and antagonist 
The opiates undergo binding to their amine-binding sites via the lone 
electron pair on nitrogen.
181
The kind of activity displayed by an opiate according to Kolb, 
depaids on whether the structural influences within the molecule could 
lead the nitrogen lone electron pair lobe to assume a characteristic 
directionality needed for binding either to the agonist or antagonist
96,
site. When this direction is not rigorously maintained, a mixed 
activity ensues.
However, contrary to the above proposals is the generally held
belief that the opiate nitrogen interacts with the opiate receptor
42 182 47in its protonated form ' . Furthermore, Shiotani et al. , reported
analgesic activity in a pair of homobenzomorphans (3.56 and 3.59)
where electron pair on nitrogen project towards the benzene ring
and away from it respectively^ and thus came to the conclusion that
orientation of the nitrogen electron pair of benzomorphan and
morphinan analogues does not account for structurally induced variations




From all the above, it is clear that there is no consensus 
regarding the nature of opiate receptor-ligand interactions. Never­
theless, it would appear that electron density of the nitrogen 
is relevant to opiate activity.
129A further investigation of the suggestion by Parfitt and Walters
97.
led to the preparation and analgesic testing (mouse hot plate) of 
3,3-disubstituted 5-methyl and 3-monosubstituted 5,9-dimethyl-6,7- 
benzomorphans. The results of this investigation are illustrated in 
Table 12.
On the assumption that the pharmacokinetic factors governing drug 
absorption and transport are uniform for the benzomorphans examined, 
attempts are made to explain the results obtained in terms of the 
events at the .receptor .Taking 2,5-dimethyl-6,7-benzomorphan hydro­
chloride as the "parent" compound, insertion of an equatorial 3- 
methyl group as in 2 ,3 ,5 -±rinethyl-6 ,7-benzomorphan HCl (3.5) (entry 
2, Table 9) gave a small increase in analgesic potency, whereas the 
axial 3-methyl isomer (3.6 HCl) resulted in a twofold reduction in 
activity. This reduction in the axial 3-methyl derivative where no 
hindrance is apparent, suggests that lone pair hindrance in the equa­
torial 3-methyl compound probably does not affect activity. More 
importantly, it seems the analgesia observed is more likely to be a 
function of the overall molecular geometry of the benzomorphan.
This assertion is supported by the consistent loss of activity shown 
by axial 3-alkyl (3.36 and 3.39) and 3-aralkyl (3.40 and 3.41)substi­
tuted cis-2 ,5,9-trimethyl-6,7-benzomorphans (cf. entries 8 - 1 1  with 
entry 7, Table 9 ). It is possible therefore, that the differences 
observed between the 3- and 4-methyl positional isomers by Parfitt 
and Walters is a result of direct participation of the substituents 
in binding to the receptor, or accounted for by some other yet unknown 
molecular factors.
The activities of the 3,3-disubstituted compounds (3.32 - 3.34; 
entries 4 - 6 ,  Table 9 ) are accounted for in terms of the contributions
98
Table 9. Ariilgesic activity of bobe 3-moncs'jbstituted and 3-diB'jbstitut*d 6,7-ben2.oo>orphar.s
Sr. tr y Compound "l " 3 S ^^50mg/kg
Ref
1 CH H H H H 11.05 102
2 (3.5) CH. CH H H H 10.6
3 (3.6) H H 24.7
4 (3.32) - 3 -CH^Ph H M b
5 (3.33) CH 3 -CH CH=CH CH 3 H H 3.7
6 (3.34) CH CH 3 -CH.CH-CH. H H c
? (3.13) CH^ " H ^ H 13.3
6 (3.3f) CH 3 H CH H 14.B®
9 (3.39) CH) H -CH CH H c
1 0 (3.40) CH H ^ U j P h H b
1 1 (3.41) CH H -(CH_).Ph H CH: b .











Footnote to Table 12.
a) The compounds were tested as hydrochlorides for analgesic activity by the Eddy-Len.oach 
mouse hot-plate procedure employing caesaricm derived general purpose mice (CDCPJ at 
the National Institute of He a It),, Bethiseda U.S.A.
b) No-dose respxjnse
c) Insufficient activity (toxic)
d) Coopoui.d tested as hydrobromide.
99.
of the axial and equatorial substituents, as observed in the mono­
substituted compounds. Although synthetic difficulties precluded the 
preparation of 3,3-dimethyl compound, both the 3-benzyl (3.32) and 
3-ally1-3-methyl compounds (3.33 and 3.34) were obtained. The lack 
of activity of 3-benzyl-3-methyl-6,7-benzomorphan {trans 3-Me/5-Me, 
3.32} is not unexpected from an axial methyl group, as in the axial 
3-methyl compound (entry, 2, Table 9 , but the lack of data on the
equatorial 3-benzyl group prevents the assessment of its contribution 
towards the activity seen.
In the 3-allyl-3-methyl compounds (entries 5 and 6 , Table 3 
the axial 3-allyl isomer (cis 3-Me/5-Me) showed no activity. This 
is consistent with an axial orientation of the 3-allyl group in the 
compound (of. other axial substituted compounds, entries 8 - 1 1 ,
Table 9 ). However, the relatively high agonist activity of the equa­
torial 3-allyl isomer {trans 3-Me/5-Me, 3.34) is unexpected, since 
the axial 3-methyl group should cause about twofold reduction in 
activity. This observation raises some questions about the role of 
the equatorial 3-allyl group in receptor interactions, and whether or 
not the compound (3.34) is acting differently at the same receptor 
as (3.32 and 3.33 ) or acting at a different receptor.
The relatively high potency of the equatorial 3-allyl compound
(3.34), may be an indication of the large contribution to binding 
made by the carbon-carbon double bond of the 3-allyl group when 
present in the equatorial position. Similar observation has been 
made with the relative potency of 3-allyl prodines, where the 
equatorial 3-allyl compound (3.60) is 13 times, and the axial 3-allyl
100,








= 0.09 mg/kg ^^50 ~ mg/kg
Alternatively, another possible explanation of the higher activity
of {3.34) over (3.35) is to consider the former as a mixed agonist
and antagonist similar to nalorphine and pentazocine. In Snyder's
proposal to explain the activities of such mixed agonists - antagonists,
the N-allylgroup of the molecule is considered to be flexible and
freely rotating, so that at any given time some molecules are in
40the antagonist form and some are not . An examination of the models 
of equatorial 3-allyl {3.34) and axial 3-allyl compound (3.33) re­
vealed that the equatorial 3-allyl group is capable of free rotation 
whereas, the axial 3-allyl group is hindered by both the benzene 
ring and the equatorial 3-methyl groups. Considering the proximity 
of the equatorial 3-allyl group to nitrogen, it is possible that 
one of the allyl orientations was fixed in a position favourable for 
interaction with the agonist conformation of the receptor. Compound
(3.34) is being evaluated for antagonist activity, the result of which 
will indicate whether an orientation favouring interaction with the
loi.
antagonist conformation is possible, and thus support or diminish 
the application of Snyder's proposal.
It is reasonable to expect an enhanced analgesic potency after 
the inclusion of a 2'-phenolic hydroxyl group in non-phenolic 6,7- 
benzomorphans. Thus, phenolic analogues of iV-alkyl-3,5-dimethyl 
and 2,4,5-trimethyl-6 ,7-benzomorphan were prepared and tested. The 
results are shown in Table 1 Q
As expected, the W-methyl (3.47) and N-allyl(3.50) compounds of 
cis-3,5-dimethyl-6 ,7-benzomorphans showed an enhanced agonist 
activity, the former as active as morphine and the latter one quarter 
as active. However, there was no change in agonist activity of the 
N-cyclopropylmethyl analogue (3.51) (of. entry 12, Table 9 with 
entry 4, Table 10). This result for (3.51) implies that either the 
phenolic hydroxy group is not properly positioned to take part in 
the presumed H-bonding receptor interactions leading to higher 
affinity and intrinsic activity, or its binding in a new receptor 
location does not contribute significantly to the activity observed. 
It is also worthwhile to note the high analgesic potency of the 
N-allyl (3.50) and N-cyclopropylmethyl (3.51) derivatives of 2'- 
hydroxyl-3,5-dimethyl-6,7-norbenzomorphan, compared to the analogous 
derivatives in the cis-5,9-dimethyl isomer (cf. entries 3 and 4 
with 6  and 7, Table ] O) .
Finally, the unexpected loss of activity of the 2'-hydroxyl- 
analogue of 2,4,5-trimethyl-6 ,7-benzomorphan (3.54) is puzzling 
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that either there may be different receptors for the phenolic and 
non-phenolic benzomorphans, or that the molecular geometry responsible 
for activity of the non-phenolic coir pound is disrupted by a phenolic 
2 '-hydroxyl group as in (3.54). If this is the case, the concept 
of enhanced analgesic activity with introduction of phenolic 
hydroxyl group into 6 ,7-benzomorphan will prove not to be of general 
application.
In summary, from the preparation and pharmacological evaluation 
of more 3-alkyl monosubstituted (equatorial and axial) and 3,3-dialkyl 
substituted 6 ,7-benzomorphans, the potency differences between the 
3- and 4-methyl-6,7-benzomorphans, observed by Parfitt and Walters, 
and between equatorial and axial 3-alkyl isomers as observed in this 
work, has been explained in terms of substituent participation at 
the receptor or by some other yet unknown molecular factors, rather 
than hindrance of the nitrogen lone pair. Furthermore, the relatively 
high agonist potency of the equatorial 3-allyl-3-methyl-benzomorphan
(3.34)encouraged us to examine the possibility of a classical N- 
antagonist substituent, causing a mixed activity at the o-position 
to nitrogen. Finally, the apparent lack of activity of the 2'-hydroxyl- 
2,4,5-trimethyl-6 ,7-benzomorphan relative to its non-phenolic analogue, 
calls for a further investigation as to whether enhanced activity 
always results from the introduction of phenolic hydroxyl group into
6 ,7-benzomorphans (with particular reference to 4,5-disubstituted 
benzomorphans).
The following suggestions are made for further work to afford 
more evidence on some of the observations made above.
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a) The reduction of the 3-allyl-3-methyl-5,7-benzomorphan (3.33 
and 3.34) to the 3-n-propyl analogues, and pharmacological 
evaluation to ascertain whether the carbon-carbon double bond 
of the allyl group is contributing to the receptor binding, 
and hence, the activity observed in the equatorial 3-allyl 
compound.
b) The preparation and analgesic evaluation of various N-substituted 
derivatives of equatorial 3-allyl-3-methyl compound (3.34) with
a view to determining if the change in activity is parallel to 
that seen in equatorial 3-methyl compounds, and hence providing 
evidence as to whether the two pharmacophores are acting at the 
same receptor; and finally
c) The preparation and pharmacological evaluation of more nnn-phenolic 
and phenolic derivatives of 4,5-disubstituted 5 ,7-benzomorphans,
in particular, the 4,5-dialkyl analogues. The objective of this 
will be to establish whether dialkyl substitution optimal 
for activity in the 5,9-isomer (ô and has the same effect in 
this series. In addition, further studies on the role of the 
2 '-phenolic hydroxyl group are necessary.
105,
CHAPTER 4
Stereochemical Studies of Substituted




183The literature contains evidence of the critical influence 
of molecular geometry upon analgesic activity of 6 ,7-benzomorphan 
derivatives and this makes the establishment of the stereochemistry 
of novel 6,7-benzomorphans a desirable objective. Both and 
n.m.r. techniques may be extensively exploited in realising this 
objective. N.m.r. techniques are of value for identification and 
differentiation purposes and, in addition, and n.m.r. data 
provide evidence of the configuration and preferred conformation of 
molecules. With n.m.r., chemical shift values and coupling 
constants are of immense value in configurational assignments, while 
the use of n.m.r. for stereochemical assignment is based on the
effects of the various substituents on the chemical shifts of 
ring carbons of a model parent compound. Generally, these effects 
depend on both the nature and geometry of the substituents and are 
not confined to the nearest atom, that is the o-carbon, but extend to 
Y or 6 carbon atoms. In particular, a methyl group deshields and 
^-carbon atoms but shields y_ ones. In the present work, n.m.r. 
spectra were obtained on a spectrometer operating at 100 mHz, but 
higher field spectra (220 mHz) were occasionally necessary. The 
stereochemical deductions come frcm ^H and n.m.r. spectra of
free bases and are supported, where necessary, by the n.m• P. features 
of some of the corresponding methiodides. Same lanthanide shift reagent 
experiments are also reported.
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4.2 Configurational studies and structure elucidation
chemical shift data for a variety of alkyl-substituted 6,7- 
benzomorphans are given in Table 11. The carbon atoms in the sub­
stituents are identified by a prime on the number appropriate to the 
position of substitution within the ring system. signal
assignments for these molecules are based on comparisons with model 
compounds (two analyses of morphine alkaloids are of particular 
relevance in this r e s p e c t ) e s t a b l i s h e d  chemical shift 
parameters and single-frequency off-resonance decoupled (SFORD) 
spectra. Use is made of the following stereochemical shift relation­
ships in deductions of configuration and conformation:
a) The Y^-shielding effect^^^'^^^'^^^ 188^ This is the shielding 
effect on a resonating carbon caused by R groups in a y-gauche 
orientation to it (see Y  in 4.2).
(4.2)
190Early attempts to explain its origin attributed it to steric
189compression between promixate C-H bonds, but more recently , 
a generalised "gauche" n.m.r. effect is thought to contribute in 
part to the effect. Although its origin is still little understood, 
the y-shielding effect has proved to be of considerable value in 
conformational analysis. For example, in 6 -membered alicyclic rings.
108,
y-gauche alkyl axial substituents produce a sizeable upfield shift 
of about 3 - 7  ppm, with little or no change in chanical shift of 
the corresponding equatorial substituent. A typical example is 
provided by the chemical shifts of C-4 and C- 6  of the a-isomer of 
1,2,3-trimethyl-3-aryl-piperidine (4.2a), which are shielded ccxnpared
Me31.5 ppm
Me









to shifts of similar carbon atoms in the 3-isomer (4.2b) 188
b) The deshielding effects (in ^^C) resulting from the interaction
191 192of syn-diaxially orientated carbons ' . A typical example is
shown by the substituted trans-decahydroquinoline (4.3a), where the
methyl shifts are downfield of the corresponding shifts in (4.3b)
191and (4.3c)
c) The shielding influence of a nitrogen lone pair orbital on the
shift of an o-methyl, when a Me-lone pair antiperiplanar relation­
ship obtains ^50,188^ Lone pair shielding of this type has been
191discussed by Eliel and Pietrusiewicz for some N, 2ô - and N-23^ 
dimethyl trans-decahydroquinolines. Further example.is provided
109
by the isomers of 1,2,3-trimethyl-3-aryl-piperidine (4.2a and 4.2b),
where the shielding influence of the nitrogen lone pair moves the
C-2 axial methyl chemical shift in (4.2a) upfield relative to the









d) The anisotropic shielding influence of an aromatic ring (in H
n.m.r. spectroscopy), especially on the protons of alkyl substituents
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9-Methyl derivatives of the 6 ,7-benzomorphan (4.4a) are first 
discussed. The secondary amine (4.4i>) (Table 11, entry 1; p. 110) is 
viewed as the parent and model for the series, because the stereo­




"2 *'3 Conf iguration* Generic name
a) H H H
b) H Me H cis-
c) Me Me H cis- a-metazoc i ne
d) Ph(CH2)2 cis- p-hexazocine
e) Me2 C=CHCH2 Me H cis- Pentazocine
f) H H Me trans-
g) Me H Me trans- 3 -metazocine
The assignment of a cis-5,9-configuration to the major isomer (4.4c)
is supported by rates of quaternisation measurements^^^, n.m.r.
analyses^^^' and, in the case of the'2-allyl derivative. X-ray
193crystallographic studies . (Entry numbers refer to Table 11 unless 
otherwise stated). Chemical shift assignments of (4.42?) were mostly
115
trivial. The quartet centred on 25.9 ppm in the off-resonance spectrum
was assigned to C-5 methyl carbon and this assignment is confirmed
by the presence of a resonance near 26 ppm in all spectra (an
equatorial 5-methyl substituent is common to all derivatives). The
assignment of the highest field triplet (32.1 ppm) to C- 8  was supported
by the pronounced upfield shift of this resonance (23.02 ppm) seen
after W-methylation (entry 2) , a consequence of the y-effect of an
equatorial N-methyl group. Similar shifts of the analogous C-10
carbon of certain N-desmethylmorphine derivatives have been noticed
184after iV-methylation . Derivatives of clinical importance - o-meta- 
zocine (4.4c), phenazocine (4.4d) and pentazocine (4.4e) - are dis­
tinguished by resonances due to the ^-substituents (entries 2, 4 
and 5). In addition, compounds (4.4d) and (4.4e), with W-alkyl 
substituent larger.than methyl, also showed a slight upfield shift 
at C-3 due to the additional y^-effect. The C-4 chemical shifts of 
the two trans-(3)-5,9-dimethyl derivatives (4.4f and 4.4gj (entries 
6  and 7) are upfield, and those of C- 6  and C- 8  downfield, of the 
corresponding resonances of the cis-analogues (4.42? and 4.4c), in 
confirmation of the axial orientation of C-9 methyl in the former 
compounds. Axial 9-methyl has a y-shielding influence at C-4, while 
the same effect of equatorial 9-methyl at C- 6  and C- 8  in the cis- 
derivative is absent. Unlike the corresponding 9-methyl proton 
shift data^^^'^^^, the C-9 ^^C shifts of the pairs do not 
provide any stereochemical information.
The diastereoisomeric non-phenolic 3,5-dimethyl analpgues of 
4.4a (3.5 a, major; and 3.6 minor) are considered next. The 
pronounced proton chemical shift difference between the o_ and ^- 
3-methyl protons (a = 0.9, 3 - 0 . 5  ppn) points to the minor isomer
116.
(3.5) = Me; = H
(3.6) R^ = H; R^ = Me
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having a trans 3-Me/5-Me configuration (with respect to the piperidine 
ring) since the 3-methyl is positioned well within the shielding 
zone of the aromatic ring. This conclusion is confirmed by n.m.r. 
analysis of the two isomers (entries 8 and 9). For the major isomer
(3.5), the assignment of the two methine carbon resonances (C-1 57.0,
C-3 51.6 ppm) was made by comparison with the corresponding shift
data for the o_-5,9-dimethyl analogue (entry 2 ) , while of the three
triplet resonances (51.8, 41.7 and 29.4 ppm), the highest field is
clearly due to C-8 , and the lowest field to C-4 (cf. C - 8  of _B-meta-
zocine and C-4 of o-metazocine, entries 6  and 2 respectively). The
chemical shift of C-9 of the benzomorphan skeleton is little affected
by méthylation, contrary to an expected o^-deshielding effect (compare
entries 2 and 8 ). Such an anomaly has previously been noted for
piperidine derivatives with 3,4-dimethyl substituents and this has
been attributed to ring deformations caused by the relief of gauche
194interactions between vicinal methyl groups . In the minor isomer
(3.6), the C-1 and C-5 resonances are shifted upfield by approximately
3.5 ppm, and the C - 8  resonance is 3.2 ppm downfield of the corres­
ponding shifts of the major isomer (entries 8 and 9), in support of
an axial orientation of the 3-methyl which would have a y-shielding
influence at C-1 and C-5 and a 1,3-syn-diaxial deshielding effect
at C-8 . The pronounced difference in chemical shift between the 3-
methyl resonances (ô  22.1,_3 16.7 ppm) provides a further example of
the shielding influence of a nitrogen lone pair orbital when in an
antiperiplanar relationship to methyl, as in (3.6)^^^'^^^. In the
195related isomeric 9-methyl-l-azabenzomorphan pair (4.5) , both
with a gauche methyl-lone pair orientation, the chemical shift diff­
erence between the axial and equatorial methyl carbon is minor.
118,
V ® ^ 1 4 . 2 6  ppm
' ^ ^ ^ 1 5 . 2 4  ppm
(4.5)
In the case of (3.5) and (3.6), aromatic shielding may also 
contribute to the chemical shift difference between a_ and 
3-methyl resonances.
The next group of substituted 6,7-benzomorphans for consideration 
are the 3-alkyl-5,9-dimethyl derivatives (3.36- 3.41) prepared from 
3-cyano-5,9-dimethyl-6,7-benzomorphan (3.36). In both the precursor 
and products, mixtures of diastereoisomers are produced as judged 
from the n.m.r. spectra of the total solid product, but the following 
n.m.r. analyses refer to the major isomers, isolated in pure form, 
in all cases. The n.m.r. features of the cyano compound (3.36) 
are similar to those of o-metazocine (4.4c) and compound {3.11)
(cf. entries 2, 3 and 10), except for the C-3 and C-4 shifts which 
are to lower field as anticipated from the deshielding influences 
of the cyano substituent. The relative magnitudes of shielding,
+ 1.03 and + 4.44 ppm is indicative of an equatorial cyano 
group^^^^. More evidence from vicinal coupling constant measurements
119,
(3.11) R = H
(3.36) R = c:N
(3.36) R = Me
(3.39) R Et
(3.40) R = CHgPh
(3.41) R =
( J values) between the C-3 position and the ^-CH^ was sought to 
corroborate this assignment.
It has been established that the most important factor influencing 
vicinal HH couplings is the dihedral angle (# between the
protons. i is the angle between the planes containing the C-C-H'
bonds and that containing the C-C-H bonds. The relationship between
3 197vicinal coupling constant ( J) and  ̂ is illustrated in Figure 2,
This representation implies that values will be largest when
vicinal protons are trans- coplanar (<}) = 180°) , slightly smaller
when they are cis-coplanar ((j) = O), and around zero when the protons
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Figure 2. Relationship between the dihedral angle,# , and
197vicinal coupling constants
One of the most important consequences of this relationship is
that the order of magnitude of diaxial, axial-equatorial and diequa-
3 3 3torial co\ç)ling constants ( and respectively), in
a piperidine ring chair system can be predicted from a knowledge of
#. The coupling constants generally fall within the ranges
3 3 3 198 3
8 - 14 Hz for J and 1 - 6 Hz for J and J . The Jaa ae ee
data obtained by measurement of dihedral angles and estimation of 
associated vicinal coupling constants concur with the observed values, 
and indicate a cis 3-CN/5-Me configuration for (3.36). The axial 
C-3 proton in (3.36) is expected to couple with one axial and one 















































is expected to be a doublet of doublets, arising from the C-3 
axial hydrogen and 4-Ha doublet (J = 8 - 14 Hz), each of which 
would be split again into a doublet by the adjacent C-4 equatorial 




A 220 mHz spectrum of 3.36 (Fig. 3; partial reproduction) revealed
3 3a well resolved doublet of doublets near 3 ppm ( j 12 Hz, jaa ae
3.5 Hz),typical of axial-axial and axial-qquatorial proton coupling,
2 3a broad triplet at 2.02 ppm ( J and J about 12 Hz) and a doublet
3 2of doublets at 1.68 ppm ( J 3.5 Hz, J 12 Hz), which are reasonably 
attributed to 3 -H^/4 -CH2 protons. Of the three multiplets specified 
above, the higher field pair were resolved at 100 mHz (Fig. 4a)^ 
all three became resolved and shifted downfield in the presence 
of excess lanthanide shift reagent Eu(fod)^ (Fig. 4b), as did the 
minor signals, such as the low intensity 9-methyl doublet together 
with a low-field multiplet near 4.5 ppm (with separation 5 Hz)
that is probably due to 3-H^ of the axial 3-cyano ccanponent (see
Fig. 3). The isomeric nature of the cyano derivative, even after
further recrystallisations, was confirmed by a long run ^^C n.m.r.
spectrum which showed several low intensity resonances that were 














Fig. 4. Portion of lOO mHz ^H n.m.r. spectrum of 3-cyano-2,5,9-tri-
methyl-6,7-benzomorphan; (a) in CDCl^ (b) after addition of
Eu(fod)^, 34 mg in CDCl^.
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Clear evidence of an eixial orientation of C-3 methyl in (3.35) 
is its high field H (0.42 ppm) and ^^C (16.5 ppm) resonances relative 
to the 3-methyl shifts of the isomeric 3,5-dimethyl derivatives (entries 
8 , 9 and 11), and the lowfield C- 8  chemical shift (27.4 ppm) compared 
with the C- 8  shift (23.0 ppm) of o^-metazocine (entry 2) which is a 
result of syn-diaxial deshielding. ^^Shielding effects of the axial 
3-methyl at C-1 and C-5 are unusually low, as judged by the corresponding 
shifts of o-metazocine and 3.6 (entries 2, 9 and 11), and suggest 
some deformation of the tri- compared with the di-C-methyl substi­
tuted molecules. Data in the 3-ethyl analogue 3.39 (entry 12) 
also support a trans-3-R/5-Me configuration with an axial substituent 
at C-3. The evidence comes from correct assignment of the two higher 
field triplets, achieved by selective decoupling experiments. In a
selective decoupling experiment, the proton resonances due to the
1
carbons in question is identified in the H n.m.r. spectrum. These
protons are then completely irradiated at low radio frequency power.
The result observed in ^^C experiments is that the carbon attached
to such protons collapses to a singlet, while other protonated carbons
199retain some C-H coupling . For (3.39), the proton irradiation at 
the C- 8  benzylic proton resonance near 2.8 ppm resulted in an 
intense singlet at 28.0 ppm and a broadened signal at 2 1 . 8  ppm 
indicative of a residual C-H coupling (Fig. 5b); similar irradiation 
at the MeCHg resonance near 1 . 8  ppm produced the reverse effects.
Thus, the 28.0 ppm triplet in the off-resonance spectrum of (3.39) 
could be unec[uivocally assigned to C-8 , and the signal at 21.8 ppm 
to the C-3 ethyl methylene carbon. All shifts except those of the 
3-R substituents t ^ s  correspond closely for spectra of (3.38 













Fig. 5. Data frcxn a selective decoupling experiment of the C - 8
benzylic methylene carbon protons in 3-ethyl-2,5,9-trimethyl-
6,7-benzomorphan. (a) Proton noise decoupled spectrum 
(b) selectively decoupled spectrum.
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unusually high field chemical shift in accord with its axial orien­
tation and antiperiplanar relationship to the nitrogen lone pair 
orbital. This high field shift of the methylene carbon of 3-Et 
becomes more apparent when it is compared with the corresponding 
data on 3-ethylcyclohexane ( 6 CH^ Me, 31.0 ppm)^^^^. Similar argu­
ments support a trans-3-R/5-Me configuration for the 3-benzyl and 
3-(2-phenethyl) analogues (3.40) and {3,41) (entries 13 and 14 
respectively).
The final group of derivatives are the 3-substituted-3,5-dimethyl- 
benzomorphans (3.32- 3.34), obtained frcm the 3-cyano analogue (3.26).
(3.,26) CH], ^ 2  = -CN
(3,.32) CH^Ph,
^ 2  = Me
(3..33)
^ 1  = C H 3 -CH2CH=CH
(3..34)
* 1  = -CH^CH=CH^, ^ 2  = Me
General points about the n.m..r. features of (3.26, 3.32 - 3.34) 
(entries 15 - 18) are the shifts of the N-methyl and C-3 resonances
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to higher and lower field respectively, compared with the corres­
ponding shifts of the other derivatives (3.5 and 3.6), a result 
of the disubstitution at C-3; two ^-effects at N-CH_ emd two a- 
effects at C-3. The shifts of the C-1, C-5 and C- 8  carbons provide 
no information on the stereochemistry in these cases, since all 
derivatives carry axial substituents at C-3. Clear evidence of the 
stereochemistry was provided, however, by the n.m.r. spectra of 
the major (ô) and minor (̂ ) 3-allyl derivatives, which were both 
isolated in a pure state. Comparative shift values of the 3-methyl 
protons (ô 1.05, ^0.32 ppm) and vinylic protons of the 3-allyl 
group (a near 5.2, 4.1; ^  near 5.8, 5.0 ppm. Table 7) established 
the cis-3-Me/5-Me configuration of the major isomer with an equa­
torial methyl group at C-3. The axial orientation of the 3-allyl 
in the same isomer is substantiated by the vinylic chemical shifts, 
which are to higher field of those of the B-isomer as a result of 
aromatic shielding. It is also consistent with the assignment of 
a(cis)- and ^(trans)-3-Me/5-Me that the o-C-3' ^^C chemical shift 
should be to lower field, and the o-methylene carbon of the allyl 
group to higher field, than the corresponding ^-resonances (entries 
17 and 18). The 3-benzyl derivative (3.32) is assigned a trans-
3-Me/5-Me configuration on the basis of its 3-methyl proton shift 
(near 0.38 ppm). Other ^^C n.m.r. features, notably the C-3' 
shift of 20.75 ppm, are close to those of the ^-3-allyl derivative 
of the same configuration. Finally, the 3-cyano derivative (3.26) 
with a 3-methyl proton chemical shift near 1.3 and a ^^C shift 
of 28.2 ppm (both comparatively low field values) is assigned the 
cis-configuration with an axial cyano substituent.
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Quaternary Salts
The value of quaternary salt n.m.r. data as an aid to the con­
figurational assignment of substituted piperidines has recently been 
192demonstrated . Hence, spectra of methiodides of some of the 
present 6 ,7-benzomorphan derivatives have been analysed to corroborate 
the stereochemical deductions drawn from the study of the bases.
The methiodide of o-metazocine (4.4c) is the model for the quaternary 
salt series.
(Iodide anion omitted 
in this and subsequent 
quaternary salt formulae)
(methiodide of 4.4c)
Although spectra of bases were obtained from solutions in CDCl^ and 
the salts from solutions in DMSO-d^, the free base-quaternary salt
data may be compared as solvent effects are considered negligible 
as judged by the essentially identical chemical shift data on the 
non-phenolic analogue of (4.4c, entry 3) in both CDCl^ and DMSO-d^ 
solvent.
Free base-quaternary salt n.m.r. comparisons (entries 2 
and 23) show that N-methylation of (4.4c) produces downfield shifts
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at C-1 and C-3 (^-effect of additional N-Me) and C- 8  (+1.2 ppm,
deshielded by antiperiplanar N-Me), and upfield shifts at carbons
4-6, 9-, 5' and 9’. The upfield effects are attributed to the
positive charge on nitrogen (as in iV-protona tion) and, at
C-4 and C-9, to the y_-effect of the axial N-methyl group. Of the
two iV-methyl resonances, the one at higher field (50.6 ppm) is
assigned as axial since it is subject to greater steric polarisation.
The lower field resonance (53.1 ppm) is associated with the equatorial
group. This assignment is supported by comparison of the spectra of
the methiodide (4.6a) and the corresponding trideuteromethiodide
202(4.6b) of 4-t-butyl-l-methyl-piperidine . The higher field N- 
methyl resonance of (4.6a) was absent in the spectrum of (4.6b). This 
missing signal must therefore be due to the axial N-substituent, 






as expected from a preferred axial course of méthylation of an 
equatorial N-alkyl conformer^^^. A typical feature of all N-methyl 
resonances in the spectra of the methiodides examined was their 
broad nature, a result of N-C couplings^^^. The difference between 
the N-methyl shifts of ametazocine methiodide and those of the
methiodide of simple piperidines such as, l-methyl-4-phenyl-4- 
piperidinol (4.7) may be explained by the presence of an o-axial 
carbon C- 8  in the benzomorphan.
130.
I ^^46.37 ppm
55.95 ppm I ^
(4.7)
Ph
192Previous studies of simple mono- and di-C-methyl derivatives 
of N,N-dimethylpiperidinium iodide show that ^-equatorial methyl 
shields both #-methyl carbons, with greater effect upon the axial 
group (4.8), while a-axial methyl shields equatorial W-methyl and 
deshields axial W-methyl (4.9).
CH -5 to 
-6 .5 ppm
-2 to -3.5 ppm
(4.8)





The upfield shifts observed is attributed to steric compression 
resulting from y-gauche interactions, but the basis of antiperiplanar 
Me/Me deshielding is little understood. Similar shielding influences
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of o-methyls on the N-methyl resonances of piperidinium salts
204have also been observed
The chemical shift data for ^-metazocine methiodide (entry 24) 
are consistent with the retention of the piperidine chair conformation 
A, in spite of the unfavourable syn-diaxial interaction between the 
axial N-methyl and C-9 methyl groups; the deshielding consequence 
of such an interaction is apparent from the lower field shift of 




(methiodide of 4.4gr, partial formula)
of the o-salt (cf. axial N-methyl data for the isomeric 3-methyl
derivatives of (4.7); a 47.3 ppm with equatorial 3- m e t h y l 51.3 ppm
192with axial 3-methyl)
The N-methyl shift data for 6,7-benzomorphans with C-3 (o- 
carbon) substituents is interpreted in terms of anticipated shielding 
effects at both N-methyls when the substituent is equatorial, and 
upfield shifts of equatorial N-methyl and downfield shifts for axial 
N-methyl when the substituent is axial. Thus, methiodide N-methyl 
shift data for the 3,5-dimethyl derivatives (3. 5) and(3.6) (entries
132.
25 and 26) confirm an equatorial orientation for 3-methyl in the 
a; both N-methyl resonances shielded in comparison with model values, 
and an axial placement in the ^-isomer, equatorial N-methyl deshielded 
relative to the standard. The N-methyl shifts of the latter isomer 
are close to those of the methiodides of the 3-substituted 5,9- 
dimethyl derivatives 3.38 and 3.40 (entries 27 and 28), also assigned 
axial carbon substituents at C-3, CH^ and CHgPh, respectively. Other 
^C n.m.r. features diagnostic of stereochemistry in benzomorphan 
bases, such .as the relative a/A. C-1, C-5, C- 8  and C-3' shift of the 
isomers (3.5) and (3.6), are also apparent in the methiodide spectra.
Substituent effects of o-methyl groups on N-methyl proton shifts 
are qualitatively similar to those on corresponding ^^C resonances^^^, 
and proton chemical shift data for the quaternary salts studied in 
this work corroborate the conclusions of configuration based on 
^^C n.m.r. spectra. (Table 12). Taking the N-methyl resonances 
of o_ and g-metazocine as standards (Table 12, entries 1 and 2), shielding 
effects are found for both N-methyl signals of the a-3,5-dimethyl 
derivative 3.5 (Table 12, entry 3) in accord with its equatorial 
3-methyl substituent, while shielding at equatorial N-methyl and 
deshielding at axial N-methyl is apparent for the axial 3-methyl 
derivatives (3.6 and 3.38; Table 12, entries 4 and 5). The N-methyl 
assignments of 3.40 (Table 12, entry 6 ), made on the basis of the 
axial N-methyl shifts of (3.6 and 3.38) show that the axial 3-benzyl 
substituent has a marked deshielding influence on the equatorial 
N-methyl group, which was shown by the use of models to lie close to 
the aromatic plane of the benzyl group in the preferred conformation 
of the molecule. Chemical shift differences between isomeric
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Table 12. chemical shifts of methiodides of some 6 ,7-benzomorphan
aderivatives; in DMSO-d 6̂
Entry ^bCompound eq-N-Me ax-N-Me 3-Me 5-Me 9-Me
1 4.4c (a) 3.35 3.23 - 1.38 0.83
2 4.4g (̂ ) ̂ 3.32 3.20 - 1.30 1.38
3 3.5(a) 3.26 3.15 1.14 1.44 -
4 3.6(6) 3.22 3.44 0.63 1.43 -
5 3.38 3.26 3.42 0.64 1.38 0.84
6 3.40 (3.58) (3.46) - 1.31 0.84
a) Values in ppm from TMS; shifts in parentheses may be interchanged
b) Base from which methiodide salt is derived
c) Previous data of N Me shifts in error (Ref. 151)
C-methyl resonances are of the same kind as those described for 
corresponding bases. For example, the o/^-9-methyl resonances of 
the metazocines (4.4c and 4.4g) and the 3-methyl resonances of (3.5) 
and (3.6).
2 '-hydroxy-6 ,7-benzomorphans
The assignment of the chemical shifts of 2,5-dimethyl-6,7- 
benzomorphan (3.45) (Table 13, entry 1) was accomplished by comparison 
with the model compound {4.4b) (Table 11, entry 1). The slight 
downfield shift at C-3 (about 4.2 ppm) is a result of the ^-effect of 




y-shielding effect. The observed upfield shifts at C-5 and C-9, 
is due to the loss of and ^ deshielding effects of C-9 methyl group 
as in {4.4b),
The 2'alkyl-3,5-dimethyl benzomorphan derivatives are considered 
next. Clear evidence of the equatorial orientation of the C-3 methyl 
group in (3.47) are its chemical shift at 0.93 ppm (Table 8 , entry 
2) and ^^C shift at 20.53 ppm (Table 13, entry 2),values comparable 





(3.47) R = Me 
(3.49) R = H
(3.51) R = -CH^-C-C^H^
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The W-desmethyl analogue (3.49) showed an expected upfield shift 
at C-1 and C-3, with a downfield shift at C-8 , the former due to the 
loss of ^-effect at C-1 and C-3, and the latter due to the loss of 
the y-effect of the N-methyl group. Other W-alkyl analogues (3.50) 
and (3.51) are distinguished by the ^^C shifts of the N-substituents 
(Table 13, entries 4 and 5) and a slight upfield shift at C-3 due 
to additional y-effect at that position compared to the N-methyl 
compound. The non-equivalence of the methylene carbons of the 
cyclopropyl group in (3.51; Table 13, entry 5), evident from the 
separate ^^C shifts, is probably due to the disruption of symmetry 
of the methylene carbons by a gauche effect of the 3-methyl.
The last series of compounds to be considered are the 2-methyl-
4,5-dialkyl benzomorphans. Synthesis of 2,4,5-trimethyl-6,7-benzo­
morphan gave one-isomer (3.54) judged to have an equatorial methyl 
group at C-4 by its n.m.r. doublet at 0.57 ppm (a value comparable
to that of the non-phenolic derivative prepared by Parfitt and 
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Walter) . In the C n.m.r. spectrum, the lack of an appreciable 
y-effect at C-9, expected of a C-4 axial methyl (similar to that shown 
by axial C-9 methyl isomer at C-4, Table 11, entry 6 ), along with 
a downfield shift at C-3 characteristic of an equatorial methyl 
group, lent support to this assignment. Lastly, the N-Me ^^C shift 
in (3.54) is slightly upfield of that in (3.45) as a result of the 
y-effect of an equatorial 4-methyl group.
137.
CHAPTER 5
2-Amidino-5,7-Benzomorphans as Potential Analgesics
138,
5.1 Introduction
The interest in guanidine derivatives stems principally from the 
discovery of high biological potency in a number of natural and 
synthetic agents possessing the group either in the free or cyclic 
form. Tetrodotoxin (5.1) and saxitoxin are examples of animal and 
natural products that elicit a dramatic blocking of axon transmission 




The former may be isolated from the ovaries of the Japanese gold­
fish and the Pacific blue ring octopus, whereas the latter is a 
seasonal algal toxin ingested by shellfish, A notable synthetic







A number of guanidine derivatives have been investigated not
only for their effects on the cardiovascular system, but also as
potential oral hypoglycaemic^^^ and also as chemotherapeutic agents^^^,
An example of the latter is seen with the replacement of the terminal
amino group of the side chain of the 8 -aminoquinoline antimalarials
209(5.3) by an N'-guanidino moiety in the investigation^ of the 
effect of a change in the character of the side chain on toxicity.




(5.3) R = -CH
(5.4) R = -NH - C
In opiate-receptor interactions, the amine nitrogen and the 
lone electron pair have been proposed as being important for their 
activities, either by considering the active species as the proton- 
ated amine^' 182^ or as the free a m i n e ^ ^ ^ ' I f  this is so, 
then the preparation of 2 -amidino-6 ,7-benzomorphans (which are 
substituted guanidines) may shed light on the following: 
a) whether an increase in the basic strength and size of the 
basic centre (amidines and guanidines are stronger bases than 
amines), affects analgesic activity;
140.
and b) whether moving the charge centre from piperidine ring nitrogen 
to carbon affects activity, since infra-red studies and molecular 
orbital calculations have shown the positive charge in the guanidinium 
ion to be located in the vicinity of the central carbon atom^^^.
The preparation and pharmacological evaluation of 2-(N'-alkyl and 
aryl amidino)-5 ,9-dimethyl-6,7-benzomorphan has been attempted and 
is discussed below.
5.2 Discussion
Two synthetic routes to guanidines are in common use.
a) the addition of amines to cyanamides^^^
R;NH R,N— C =  N R,N— C = N H
NR,
b) the displacement of an alkyl mercaptan by an amine from an
212 213alkylisothiouronium salt '




A study of the scope of the latter reaction by Short and Darby
revealed that primary amines are generally more reactive than
214secondary amines, though there are exceptions
The reaction of 5,9-dimethy1-6,7-norbenzomorphan with S-methyl- 
isothiouronium sulphate in aqueous ethanol was chosen for the prepara­
tion of 2-amidino-5,9-dimethy1 -6 ,7-benzomorphan (5.6).
CHHN
NHII






However, in all reactions attempted, only starting material 
was recovered. Although it has been demonstrated that 1° amines are 
generally more reactive than 2 ° amines it was considered that 
changes of reaction conditions, for example, solvent, reaction time 
and proportion of the reactants may afford results.
The 2-(N'-arylamidino)-5,9-dimethyl-6,7-benzomorphan were 
obtained by heating 2-cyano-5 ,9-dimethyl-6 ,7-benzomorphan and 
appropriate anilinium p-toluene sulphonate in refluxing toluene, 












(5.2) R = W  // CH
(5.15) R=-^  OCH3
The products were purified by silica gel column chromatography,
and identified by ^H, n.m.r. and i.r. characteristics. However,
attempts to employ the p-toluene sulphonate salt of aliphatic
amines such as ethylamine and butyl ami ne were unsuccessful. An
insight into the failure of aliphatic amines to react can be
gained by considering the mechanism of the reaction involved.
211Odo reported that the mechanism involved a reversible nucleo- 
philic attack of the free amine on the protonated cyanamide. 
Consequently, the availability of the nitrogen lone electron pair 
in the amine dictates the ease of reaction. Aniline and other aryl
143,
RjNH ♦ R^N-CSNH — ► R;N— C = NH
INR
amines are weaker bases than, for example, ethylamine. Therefore, 
the p-toluene sulphonate salts of anilines will be stronger acids 
than those derived from ethylamine and other aliphatic amines.
So, under the reaction conditions, the arylamines will exist more 
readily as the free amine than will the alkylamines. Secondly, the 
catalysing species (H ) will be easily neutralised by stronger 
alkylamines compared with the arylamines and therefore, provides 
no driving force for the reaction to occur. A combination of 
these two factors will facilitate the reaction of the arylamines 
whilst retarding those of the alkylamines, as observed.
The n.m.r. spectra of the 2-amidino benzomorphans were 
similar (Table 14) and provide no means of identification except 
that the Ar-CH^ shift of (5.9) at 2.28 ppm and Ar-OC^^ n.m.r.
shift of (5.10) at 3.75 ppm.
However, identification was possible from the n.m.r. shift 
d ata of the compounds prepared (Table 15). Conversion of 2-cyano-
5,9-dimethy1-6,7-benzomorphan to the 2-(N'-phenylamidino)-analogue
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Table 14. n.m.r. shifts of 2-cyano and some 2-(arylamidino)-5,9-
adimethyl-5,7-benzomorphans in CDCl^ .
Compound 5-Me 9-Me 4"-R NH
5.7 1.43 0.87 (d) 
6 Hz
- -
5.8 1.40 0.87 (d) 3.92
5.9 1.40 0 . 8 8  (d) Ar-CH
2.28(s)
3.92
5.10 1.40 0 . 8 8  (d) Ar-OCH
3.75(sT
3.92
a) Values in ppm from TMS.
carbon in (5.7) from 118.32 ppm to 152.07 ppm, indicating the
presence of ^C=NH. Both the 2-(p-tolylamidino) and 2-(p-anisyl-
 ̂ \amidino) derivatives showed a C=NH carbon shift near 152 ppm
(Fig. 6 ) . The shifts of other aromatic carbons in the molecule 
provide the evidence for the presence of the amidino aromatic 
ring, and also serve to distinguish the various compounds themselves, 
Thus, a downfield shift of the aromatic carbon (C-4") caused 
by the 4"-CH^ and 4"-0CH^ groups is observed, as well as shielding 
effects at the ortho and para carbons (C-3" and C-1") (Fig. 6 ). 
Compounds (5.9) and (5.10) were submitted for pharmacological 
evaluation.
Pharmacology
Data from the pharmacological evaluation of (5.9) and (5.10) 





















































(5.8) proved to be without analgesic activity. It is worthwhile to
note that the N'-aryl amidino derivatives prepared as a result of
synthetic difficulties with the N'-alkylamidino analogues, are
weaker bases, and secondly, they might not have a symmetrical
charge distribution in the cation. Thus, if the positively charged
nitrogen centre is the pivot on which analgesics bind first to the
43breceptor as suggested by Portoghese , then a shift of this centre 
as in (5.8a) or (5.8i>) will displace the other substituents in the 
molecule from their productive binding positions, thereby leading 
to loss of activity.
HN cr
(5.#2) (5.8Z))
S e c o n d l y , i t  is reported that guanidinium ions bind 
less strongly to carboxylate ions of proteins than ammonium ions 
If a similar phenomenon applies at the opiate receptor, a less 
productive binding and hence,low activity might result. In 
conclusion, it is hoped that the preparation and evaluation of 
unsubstituted 2-amidino-5,9-dimethyl-6,7-benzomorphan and some 






All melting points (uncorrected) were determined on a Town son 
and Mercer melting apparatus. The infra-red spectra (liquids as 
films, solids as KBr discs or Nujol mulls) were recorded on a 
Unicam SP 1025 spectrophotometer.
Routine 60 mHz n.m.r spectra were recorded on a Perkin-Elmer 
R12B and JEOL JNM-PMX 60SI n.m.r. spectrometers, 100 mHz spectra 
on a JEOL PS 100, and the one 220 mHz spectrum (p.121 ) was 
recorded by the Physicochemical Measurement Unit (PCMU), Harwell.
Proton and off-resonance decoupled spectra were obtained 
from a JEOL FX 90Q n.m.r. spectrometer operating at 22.5 kHz. 
Samples were prepared in 5 ram o.d. tubes as approximately 10% 
solutions in CDCl^ with 2% SiMe^ as reference. The deuterium of the 
solvent provided the lock signal. Spectra were recorded with 8 K 
data points; the probe temperature was 23°C. For an average 
spectral width of 5000 Hz, a 4s pulse corresponding to a tilt 
angle of 30^ was employed with a 1.8192s interval between pulses.
Mass spectra were measured on a VG Micromass 7070 E mass 
spectrometer operating at 70 eV (El), and with Xe/Glycerol for 
fast atom bombardment (FAB).
Elemental analysis were carried out by the microanalysis 
section of the School of Pharmacy, Brunswick Square, University of 
London.
Dried solvents were distilled from lime and stored over'type
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4A molecular sieves, or were dehydrated with freshly pressed sodium 
wire. Distillation under pressure was carried out in a Buchi GKR-50 
glass tube oven.
2,3,5-Trimethyl-6,7-benzomorphan (3.5 and 3.6)
129The method employed was that of Parfitt and Walters
An ice-cold stirred suspension of 2,4-lutidine methiodide (75 g) 
in dried ether (100 ml) was treated with about 400 ml of ethereal 
benzyl magnesium and benzyl chloride 75 ml). The mixture was stirred 
vigorously for 2 hr in the cold and then added to a mixture of 50% 
perchloric acid (150 ml) and crushed ice (500 g) to give a three 
phase mixture. The product which precipitated in the centre layer 
was collected after 30 min and washed with ethanol to give, after 
drying, 81.06 g (8 6 %) of 2-benzyl-l,4,6-trimethyl-l,2-dihydropyridine 
perchlorate. This product was suspended in a mixture of methanol 
(250 ml) and 2 N NaOH (350 ml), and treated with sodium borohydride 
(14.0 g) during 15 min. The mixture was kept at 55 - 60°C for 1^ hr 
and then diluted with water 2 0 0  ml, cooled and extracted with ether 
(5 X 200 ml). The combined ether extract (Na^SO^ dried) was evapor­
ated in vacuo to give 44.11 g of the tetrahydro product, which, 
with 47% aqueous HBr (123 ml) and 45% HBr in acetic acid (74 ml), 
was refluxed for 48 hr. The resultant solution was poured into 
ice-water, made alkaline with ammonia and extracted with ether 
(4 X 100 ml). The ether solution was extracted with 2 N HCl (3 x 
loo ml), and the combined acid solution was basified with aqueous 
ammonia. Extraction with ether (4 x 100 ml) followed by drying 
and evaporation of the ether in vacuo gave 40.60 g (92%) of the 
crude benzomorphan as an oil. Distillation over a short path at
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130^C/0.S mm Hg gave 34.57 g of pure base. The major isomer (3.5) 
was separated as the hydrochloride and the minor isomer (3.6) as 
the oxalate. Both the hydrochloride and methiodide salts of both 
isomers were prepared and recrystallised from ethanol-ether mixture,
(3.5) HCl m.p. 152 - 154°C
(3.5) methiodide m.p. 268 - 269^C (Lit.^^^ 264 - 265.5°C, 
from ethanol).
Anal, calcd. for requires C, 53.78; H, 6.77; N,
3.92%:
Found: C, 53.99; H, 7.09; N, 3.79%
(3.6) HCl m.p. 222 - 224°C
(3.6) methiodide m.p. 242 - 243°C
Anal, calcd. for requires
C, 53.78; H, 6.77; N, 3.92%:
Found: C, 53.66; H, 6.96: N, 3.84%.
cis-2,5,9-Trimethyl-6,7-benzomorphan (3.21)
2,5/9-Trimethyl-6,7-benzomorphan was prepared by the method 
described for 2,3,5-trimethyl-6 ,7-benzomorphans (3.5 and 3.6).
The perchlorate from the reaction of benzyl magnesium chloride with
3,4-lutidine methiodide (100 g) was separated into the chloroform 
soluble and insoluble portions. The chloroform insoluble portion 
was reduced with sodium borohydride and the tetrahydro product 
cyclised to give an oil which after distillation at 140°C/2 mm 
Hg gave 29.5 g of cis-2,5,9-trimethyl-6,7-benzomorphan, as shown
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by the and n.m.r. spectra of the product.
'^-Dehydro-2,3, 5-trimethyl-6,7-benzomorphan (as the iminium 
perchlorate 3.17)
Mercuric oxide (52.40 g; 240 m Mol) was added, gradually, over 
15 min, to a stirred solution of 2,3,5-trimethyl-6 ,7-benzomorphan 
(3.5; 10.42 g, 50 mMol) in 40% acetic acid (200 ml) heated under 
reflux. The mixture was refluxed for 2 hr, cooled and the precipi­
tated mercurous acetate collected and washed with 5% acetic acid 
solution (50 ml). The combined filtrate and washings were saturated 
with H^S and the resultant suspension filtered through celite.
After basification with potassium carbonate the filtrate was ex­
tracted with chloroform (5 x 200 ml). The chloroform extract was 
acidified with ether previously saturated with perchloric acid 
and the solvent removed to give the product as a solid (7.59 g;
50%). Recrystallisation from ethanol gave colourless crystals, 
m.p. 164 - 166°C.
(3.5 and 3.6) gave identical product.
-1 \  +Vmax (Nujol): 1680 cm ( C = N )
Anal, calcd. for C^gHg^NO^Cl requires 
C, 57.4; H, 6.4; N, 4.7%:
Found: C, 56.9 ; H, 6.4; N, 4.7%.




To a solution of potassium cyanide (1.20 g; 18.0 mMol) 
in water (50 ml) in a separatory funnel, was added the iminium 
perchlorate (2.0 g ; 60 mMol). The mixture was layered with ether 
(50 ml) and shaken vigorously. The ether layer was separated and 
a further extraction with ether (3 x 100 ml) undertaken. The 
combined ether extract was dried and concentrated to give the 
product as an oil (1.05 g; 73%) which crystallised on standing. 
The base was recrystallised from petroleum spirit (60 - 80°C) and 
had a m.p. 102 - 104°C.
V (Nujol): 2220 cm  ̂ (-C5N) max
Anal, calcd. for ^]^g^20^2 ^^quires
C, 79.9; H, 8.4; N, 11.7%.
Found: C, 79.9; H, 8 .6 ; N, 11.8%.
METHOD B
The method employed was that of Groutas et al.165
To a solution of 2,3,5-trimethyl-6,7-benzomorphan (3.5; 
10.50 g, 49.0 mMol) in methanol (50 ml) was added 30% hydrogen 
peroxide (30 ml.)The mixture was stirred for 48 hr and then 
heated under reflux for 5 hr. Palladium/charcoal (0.30 g) was 
added to the stirred, cooled solution (0 °), and stirring was 
continued for 1 hr. The catalyst was ramoved, the filtrate 
evaporated to small volume and dichloromethane ( 1 0 0  ml) added. 
The solution was dried over anhydrous NagSO^ and evaporated to 
give a solid (9.3 g). This was dissolved in dichloromethane
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(loo ml), cooled to 0°C and trifluoroacetic anhydride (36 ml) 
added, with stirring. After 1 hr, the mixture was heated at 
50°c for 20 min and then evaporated to give an oil. A solution 
of potassium cyanide (54 g) in water (100 ml) was added to the 
resultant oil, at 0 °, and the mixture stirred at room temperature 
for 1 hr. The mixture was extracted with ether (3 x 100 ml). The 
ethereal extracts were dried (MgSO^) and evaporated to give the 
product as an oil (7.80 g; 6 6 %) which crystallised on standing. 
Recrystallisation of the base from petroleum spirit (60 - 80°C) 
gave a light yellow solid, m.p. 102 - 104°C. and n.m.r.
data were identical with that of the product by method A.
2-Cyanomethyl-3,5-dimethyl-6 ,7-benzomorphan (3.29)
By the method B described for (3.5) above, 2,3,5-trimethyl-6,7-
benzomorphan (3.6; 14.50 g; 69.6 mMol) gave the titled product
as an oil (13.48 g; 80%) which crystallised on standing.
Recrystallisation from n-hexane gave colourless plates, m.p.
6 8  - 70°C.
V (Nujol): 2225 cm"^ (-CEN) max
Anal, calcd. for requires
C, 79.9; H, 8.4; N, 11.6:.
Found: C, 79.8; H, 8.5; N, 11.6%.
2-Aminoethyl-3,5-dimethyl-6 ,7-benzomorphan (3.30)
To a cooled and stirred suspension of LiAlH^ (0.16 g) in 
anhydrous ether ( 2 0  ml), was added a solution of 2 -cyanomethyl-
3,5-dimethyl-6,7-benzomorphan (0.5 g; 2.1 mMol) in ether (20 ml).
155,
The reaction was left stirring for 1 hr. at room temperature.
The excess LiAlH^ was destroyed by addition of H^O (0.16 ml) , 
followed by 5 N NaOH (0.12 ml) and finally H^O (0.48 ml)^^^.
The filtrate obtained after removing the precipitate was 
concentrated in vacuo to give the product as an oil (0.47 g;
92%), which was converted to the oxalate salt. Recrystallisation 
from ethanol gave colourless crystals, m.p. 190 - 192°C.
Anal, calcd. for ^20^28^2^8*^2^ requires 
C, 54.3; H, 6 .8 ; N, 5.9%
Found: C, 53.9; H, 6 .8 ; N, 6.3%.
Similar reduction of 3-cyano-2,3,5-trimethyl-6,7-benzomorphan 
(3.26) afforded an equal mixture of cis and trans-2,3,5-trimethyl- 
6 ,7-benzomorphans (3.5) and (3.6), as shown by the and 
n.m.r. spectra of the product.
3-Cyano-2,5,9-trimethyl-6 ,7-benzomorphan (3.36)
By the method B described for cyanation of (3.5) above,
2,5,9-trimehtyl-6 ,7-benzomorphan {3.11; 15.12 g, 69.5 mMol) gave 
the product as an oil (13.20 g; 78%) which crystallised on 
standing. The crude product was chromatographed on a column of 
silica gel (200 g) and eluted with chloroform. Fractions were 
collected in 30 ml portions. The pure fraction was concentrated 
in vacuo and the base which crystallised out, was recrystallised 
from n-hexane to give colourless crystals, m.p. 100 - 101°C.
V (film) : 2220 cm~^ (-C=N) max
Anal, calcd. for requires
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C, 79.95; H, 8.38; N, 11.65%:
Found: C, 79.62; H, 8.45; N, 11.84%.
3-Aminomethyl-2,5,9-trimethyl-6,7-benzomorphan (3.37)
To a cooled and stirred suspension of LiAlH^ (0.50 g) in 
anhydrous ether (25 ml) was added a solution of 3-cyano-2,5,9-tri­
methyl-6 ,7-benzomorphan (1.50 g ; 6.25 mMol) in ether (25 ml).
The reaction was refluxed gently for 1 hr, after which the 
excess LiAlH^ was destroyed with H^O (0.5 ml), followed by 5 N 
NaOH (0.33 ml) and finally H^O (1.5 ml). The filtrate obtained 
after removing the precipitate was concentrated in vacuo to 
give the product as an oil (1.35 g; 78%), which was converted 
to the oxalate and recrystallised from methanol, m.p. 165 - 168°C 
Anal, calcd. for C H N O .̂ H O requires
zo Zo z a z 
C , 55.42; H, 6.74; N, 6.46%:
Found: C, 55.02; H, 7.16; N, 6.65%.
Preparation of 3-alkyl-6,7-benzomorphans
The following are generalised procedures.
METHOD A
To a cooled and stirred suspension of the iminium 
perchlorate (3.17) in anhydrous ether was added the appropriate 
Grignard reagent solution, dropwise. The reaction mixture was 
stirred in the cold for 3 hrs, poured into ice-water and basified
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with ammonia. The solution was extracted with ether (3 x 100 ml) , 
dried (Na^SO^) and concentrated in vacuo to give the product.
METHOD B
To a cooled and stirred ethereal solution of the approp­
riate Grignard reagent or alkyllithium was added, dropwise, a 
dilute solution of 3-cyano compound in anhydrous ether. The 
reaction was stirred for 3 hr (for 3-cyano-2,3,5-trimethyl-6,7- 
benzomorphan) and overnight (for 3-cyano-2,5,9-trimethyl-6,7- 
benzomorphan), after which the reaction mixture was poured into 
ice-cold water. The ether layer was separated and the aqueous 
portion was extracted further with ether(3 x lOO ml). The com­
bined ether extract was dried (Na^SO^) and concentrated in vacuo 
to give the product.
3-Benzyl-2,3,5-trimethyl-6 ,7-benzomorphan (3.32)
By method A (2.50 g ; 8 mMol) of iminium perchlorate (3.17) 
gave the crude product as an oil (2.89 g). Short path distillation 
at 170°C/0.5 mm Hg gave pure base (2.19 g; 90%).
The hydrochloride separated as colourless plates from ethanol- 
ether mixture and had m.p. 246 - 249°C.
Anal, calcd. for ^22^28^^^ requires 
C, 77.28; H, 8.25; N, 4.10%:
Found: C, 77.48; H, 8.53; N, 4.10%.
Both the ^H and spectra of the product obtained by 
method B were identical with those of the product by method A,
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3-Allyl-2,3,5-trimethyl-6,7-benzomorphan (3.33 and 3 .34)
By method A (3.0 g ; 9.5 mMol) of iminium perchlorate (3.17) 
gave the product as an oil (1.78 g, 73%), after distillation 
of the crude product at 150^0/ 1 mm Hg. A TLC examination of 
the oil showed two major spots corresponding to the two isomers. 
The oil was chromatographed on a column of silica gel (60 g) 
and eluted with 100% chloroform, and 10%, 25%, 50% ethyl acetate 
in chloroform respectively. Fractions were collected in 30 ml 
portions. The pure minor isomer was contained in the 100% chloro­
form and 1 0 % ethylacetate in chloroform fractions and, the major 
isomer in 25% ethyl acetate in chloroform fraction. The pure 
isomers were converted to the hydrochloride salts. The hydro­
chlorides separated as colourless crystals from ethanol-ether 
mixture.
(3.33) HCl had a m.p. 246 - 247°C 
Anal, calcd. for C^gH^^NCl requires 
C, 74.07; H, 8.98; N, 4.80%:
Found: C, 73.90; H, 9.06; N, 4.84%.
(3.34) HCl had a m.p. 252 - 253°C.
Anal, calcd. for C _H NCI requireslo 2b
C, 74.07, H. 8.98; N, 4.80%:
Found: C, 73.80; H, 9.17. N, 4.84%.
The isomers from the product obtained by method B had the 
same ^H and n.m.r. characteristics as those by method A.
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2,3,5,9-Tetramethyl-6,7-benzomorphan (3.36)
By method B (2.50 g ; 10 mMol) of 3-cyano-2,5,9-trimethyl •
6 ,7-benzomorphan gave the product as an oil (1.20 g ; 50%), 
after short path distillation of the crude at 150°C/0.2 mm Hg
The hydrochloride separated as colourless crystals from 
ethanol-ether mixture, and had m.p. 268 - 270°C.
Anal, calcd. for requires
C, 72.29; H, 9.10; N, 5.27%:
Found: C, 72.43; H, 9.11; N, 5.17%.
The methiodide separated as plates from ethanol and had 
m.p. 240 - 241°C.
Anal, calcd. for requires
C, 54.99; H, 7.06%:
Found: C, 55.17; H, 7.13%.
3-Ethyl-2,5,9-trimethyl-6 ,7-benzomorphan (3.39)
By method B (3.0 g ; 12.5 mMol) of 3-cyano-2,5,9-trimethyl-
6 ,7-benzomorphan gave the product as an oil (1.40 g ; 46%), after
distillation of the crude product at 130°C/0.5 mm Hg.
The hydrochloride separated from ethanol-ether mixture as 
colourless crystals, and had m.p. 271 - 273°C.
Anal, calcd. for C^^H^^NCl requires 
C, 72.96; H, 9.37; N, 5.01%:
Found: C, 72.59; H, 9.49; N, 5.04%.
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3-Benzyl-2,5,9-trimethyl-6,7-benzomorphan (3.40)
By method B (3.0 g; 12.5 mMol) of 3-cyano-2,5,9-trimethyl-
6 ,7-benzomorphan gave the product as an oil (1.81 g, 48%), after 
distillation at 170°C/0.2 mm Hg. A TLC analysis of the oil 
showed two isomers. Attempts to separate the two isomers on 
a silica gel column resulted in the isolation of one isomer 
(major) in all cases tried.
The hydrochloride separated as colourless crystals from 
ethanol-ether mixture and had m.p. 217 - 219°C.
Anal, calcd. for C _H NCI requires22 2o
C, 77.28; H, 8.25; N, 4.10%:
Found: C, 76.93; H, 8.52; N, 4.09%.
The methiodide separated as tiny needles from ethanol and 
had m.p. 247 - 249°C.
Anal. calcd. for requires
C, 61.75; H, 6.75%:
Found: C, 62.21; H, 6.54%.
3-Phenethyl-2,5,9-trimethyl-6 ,7-benzomorphan (3.41).
By method B (3.0 g; 12.5 mMol) of 3-cyano-2,5,9-trimethyl-
6 ,7-benzomorphan gave the product as an oil (1.46 g; 40%), after 
short path distillation of the crude product at 160°C/1 mm Hg.
The hydrochloride separated as fluffy needles from ethanol- 
ether mixture and had m.p. 236 - 238°C.
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Anal, calcd. for C^^H^^NCl. requires 
C, 75.70; H, 8.29; N, 3.84%:
Found: C, 75.77; H, 8.63; N, 3.38%.
^-Méthylation of o-normetazocine
o^-Normetazocine (Ig), formic acid 98% (0.56 g) and 37% 
aqueous formaldehyde (0.17 g) were heated together on a steam 
bath for 3 hr. Aqueous ammonia solution was added to the cooled 
mixture which was then extracted with chloroform (3 x 50 ml).
The bulked extracts were dried and evaporated to dryness to 
give o-metazocine as a solid (0.95;, 89%). Recrystallisation 
from ethanol gave colourless crystals, m.p. 230 - 232°C 
(Lit.^^'^^l 231 - 233; 228 - 233°C).
Under the same conditions, g-normetazocine (0.5 g, 2.3 mMol) 
gave ^-metazocine as a solid (0.40 g. 75%) which was recrystallised 
from ethanol, m.p. 211 - 213°C (Lit.^^'^^^ 220 - 221.5; 215 - 217.5°C) 
Anal, calcd. for C^gHg^NO requires 
C, 77.88; H, 9.15; N, 6.05%:
Found: C, 77.45; H, 9.22; N, 5.84%.
2  arid _6-Metazocine methiodides
The following is a general procedure:
The sample of benzomorphan (0.5 g) was dissolved in a minimum 
amount of acetone or methanol. Excess iodomethane was added, and
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the solution thoroughly mixed. Ether was then added until the 
mixture was just about to be cloudy, and the mixture was left to 
crystallise out at room temperature. The solid which separated 
was recrystallised from methanol, ethanol or a mixture of 
ethanol and ether:
a-metazocine methiodide, m.p. 253-255°C (from ethanol
Anal, calcd. for requires
C, 51.48; H, 6.48%:
Found, C, 51.62; H, 6.46%.
^-metazocine methiodide, m.p. 238 - 240^C (from ethanol) 
Anal, calcd. for requires
C, 51.48; H, 6.48; N, 3.75%:
Found: C, 51.04; H, 6 .6 6 ; N, 3.50%.
4-Methoxybenzyl chloride
4-Methoxybenzyl alcohol (50 g) in ether (100 ml) was added 
dropwise to conc. HCl (70 ml) under ether (100 ml). After 
stirring for 45 min at room temperature the two layers were 
separated. The combined ether layer and ether washings (2 x 50 ml) 
of the aqueous layer were washed with saturated aqueous NaHCO^ 
solution (2 X 100 ml) and then with 10% aqueous sodium carbonate
solution (2 X 100 ml). The dried (NagSO^) ether solution was
evaporated to 55.0 g of crude material. Distillation over a short 
path at 120°C/0.3 mm Hg afforded the product as a clear, colour­
less oil (46.90 g; 8 8 %), which was used immediately. The ^H
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and n.m.r. spectra of the product was consistent with the 
structure.
n.m.r. spectra; OCH^C^H^CH^OH 64.25 ppm
CH^Cl 46.20 ppm
4-Methoxybenzyl magnesium chloride
A mixture of magnesium powder (15 g) and magnesium turnings 
(3 g) was vigorously stirred under refluxing anhydrous ether 
(500 ml). 4-Methoxybenzyl chloride (46.9 g) in anhydrous ether 
(250 ml) was added dropwise over a 1 hr interval and the reaction 
was left stirring for an additional 1 hr. The resulting Grignard 
reagent was filtered through glass cotton to remove the finely 
divided magnesium powder and then used in the next experiment.
2'-Hydroxy-2,3,5-trimethyl-6,7-benzomorphan (3.47)
A stirred suspension of 2,4-lutidine methiodide (25 g ;
0 . 1  mole) in anhydrous ether was treated with ethereal p-methoxy- 
benzyl magnesium chloride from above. The mixture was stirred for 
2 hr at room tenperature and then added with vigorous stirring 
to a mixture of 60% perchloric acid (60 ml) and crushed ice 
(500 g). The product, 2-(p-methoxybenzyl)-1,4,6 -trimethyl- 
1 ,2 -dihydropyridine perchlorate was filtered and washed with 
ethanol. The dihydro perchlorate (28.0 g) was added to a mixture 
of 2 N NaOH (200 ml) and methanol (150 ml), and treated with 
sodium borohydride (7.5 g).
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The mixture was refluxed for 6  - 8 hr, diluted with water 
(300 ml), cooled and extracted with ether (3 x 100 ml). The 
bulked ether extract was dried (Na^SO^) and the solvent was 
removed to give 19.20 g of 2-(p-methoxybenzyl)-1,4,6 -trimethyl- 
1,2,3,6 -tetrahydropyridine which with 150 ml of 47% aq. HBr was 
kept at 135 - 140°C for 22 hr. The resultant solution was 
poured into ice-water and made alkaline with ammonia (0 .8 8 0 ). 
Extraction with chloroform (4 x 100 ml) followed by drying and 
evaporation gave the crude product as an oil which on washing 
with anhydrous ether gave the product as a solid (6.9 g, 33%). 
Recrystallisation from ethanol afforded a solid, m.p. 234 - 
236°C.
Anal, calcd. for C^^H^^NO requires
C, 77.88; H, 9.15; N, 6.05%;
Found; C, 78.09; H, 9.30; N, 6.00%.
The hydrochloride separated as colourless crystals from 
ethanol-ether mixture.
2*-Hydroxy-2,5-dimethyl-6,7-benzomorphan (3.45)
The titled compound was synthesised from 1,4-dimethyl- 
pyridinium iodide (20 g ; 85 mMol) and ethereal p-methoxybenzyl- 
magnesium chloride (from p-methoxybenzyl chloride (39.9 g) and 
magnesium 18 g) following the same procedure described for
2,3,5-trimethyl-6,7-benzomorphan above. The product (9.0 g ;
48%) was recrystallised from ethanol, and had a m.p. 206 - 209 C 
(Lit.^°2 206 - 210°C).
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2 ' -Hydroxy-3,5-diipethy 1-6 ,7-benzomorphan {3.49)
A solution of 2 ' -hydroxy-2 ,3,5-trime thy 1-6,7-benzomorphan 
(4.10 g, 18 mMol) in acetic anhydride (10 ml) was heated together 
on a steam bath for 3 hr. The solvent was removed in Vacuo, and 
the residue was dissolved in ethyl acetate (100 ml) . After 
washing with 5% Na^CO^ solution (3 x 50 ml) the organic layer 
was separated, dried (anhy. KgCOg) and evaporated in vacuo to 
give the 0-acetylated compound (4.0 g). A solution of this 
0 -acetylated conpound in chloroform (25 ml) was added dropwise 
to a solution of cyanogen bromide (1.60 g) in chloroform (25 ml) 
at room temperature. The mixture was refluxed for 3 hr, cooled 
to room tenpe rature and washed with 5% HCl (50 ml) . The dried 
(Na^SO^) chloroform solution was concentrated in vacuo to give 
4.07 g of the crude Æ-cyano conpound. To this crude N-cyano 
conpound was added 7% HCl (80ml) and the mixture was refluxed 
overnight. After cooling, the solution was made alkaline with 
aqueous ammonia and extracted with chloroform (4 x 50 ml) . The 
bulked chloroform extract was dried (anhy. K^CO^) and concentrated 
in vacuo to give the product as a solid (2.27 g; 59%) , which was 
recrystallised from isopropanol and had m.p. 240 - 242°C.
Anal, calcd. for ^2.4^19^^ requires 
C, 77.38; H, 8.81; N, 6.45%
Found: C, 77.02; H, 9.13; N, 6.54%.
2-Allyl-2 ' -hydroxy-3,5-dime thy 1-6 ,7-benzomorphan {3.50)
A mixture of 2'-hydroxy-3,5-dimethy 1-6,7-benzomorphan 
(1.5 g; 6.9 mMol), allyl bromide (0.84 g; 6.9 mMol) and potassium
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carbonate (0.5 g) in ethanol (50 ml) was refluxed for 24 hr, 
and the solvent was removed in vacuo. The residue was taken 
up in water and extracted with chloroform (3 x lOO ml). The 
bulked chloroform extract was dried (Na^SO^) and concentrated 
to give the product as a solid (0.84 g, 48%).
The hydrochloride crystallised from butanone-methanol mixture 
and had m.p. 263 - 265°C.
Anal, calcd. for requires
C, 69.49; H, 8.23; N, 4.77%:
Found: C, 69.11; H, 8.23; N, 4.81%.
2-Cyclopropylmethyl-2'-hydroxyl-3,5-dimethyl-6,7-benzomorphan (3.51)
A solution of cyclopropylcarbonyl chloride (1.88 g ; 18 mMol) 
in tetrahydrofuran was added dropwise to a mixture of 2 *-hydroxyl- 
3, 5-dime thyl-6 , 7-benzomorphan (2.0 g ; 9.2 mMol) and triethylamine 
(1.81 g ; 18 mMol) in tetrahydrofuran (50 ml). The mixture 
was stirred at room temperature for 3 hr, after which the preci­
pitate of triethylamine hydrochloride was filtered off.
Evaporation of the tetrahydrofuran gave (3.04g; 93%) of the 
cyclopropylamide of (3.49). A solution of the cyclopropylamide 
in tetrahydrofuran (40 ml) was added dropwise to a suspension 
of lithium aluminium hydride (0.97 g) in anhydrous tetrahydrofuran. 
The mixture was refluxed for 8 hr after which the excess lithium 
aluminium hydride was destroyed with H^O (0.97 ml), followed by 
5 N NaOH (0.80 ml) and finally, H^O (2.9 ml). The filtrate obtained
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after removing the precipitate was dried (Na^SO^) and concentrated 
to give the product as an oil (1.41 g; 61%) which solidified 
on standing.
The hydrochloride separated as colourless crystals from
ethanol-ether mixture and had m.p. 280 - 282^0.
Anal, calcd. for C ^NOCl requires18 2 6
C, 69.59; H, 8.54; N, 4.55%;
Found; C,70.05; H, 8 .6 6 ; N, 4.61%.
2 *-Hydroxyl-2,4,5-trimethyl-6,7-benzomorphan (3.54)
To a cooled and stirred ethereal solution of 2-cyano-
1,4,5-trimethyl-l,2,3,6 -tetrahydropyridine (6 g; 40 mMol) 
was added an ethereal solution of p-methoxybenzyl magnesium 
chloride (from p-methoxybenzyl chloride, 18.78 g and magnesium, 
8.64 g). After 2 hr the mixture was quenched with ice (50 g), 
the ether layer was separated and the aqueous phase washed with 
ether (2 x 100 ml). The combined ether solution was extracted 
with aq. 2N HCl (3 x 100 ml), and the acid extracts were 
basified with dilute ammonia solution and extracted with ether 
(3 X 100 ml). Evaporation of the dried (Na^SO^) ethereal solution 
gave 2-(p-methoxybenzyl)-1,4,5-trimethyl-l,2,3,6 -tetrahydro­
pyridine (8.2; 83%), which was heated in boiling aq. 47% HBr 
(60 ml) under reflux for 22 hr. The cooled solution basified 
with dilute ammonia, was extracted with chloroform (4 x 100 ml), 
the chloroform solution was extracted with 2 N HCl (3 x 100 ml) 
and the combined acid extracts were basified with dilute ammonia 
solution. Chloroform extraction (4 x 100 ml) followed by
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evaporation of the dried (Na^SO^) extract gave the product as 
a solid (2.46 g; 32%).
The hydrochloride separated from ethanol-ether mixture as 
colourless crystals and had m.p. 283 - 285°C (with decomposition)
Anal, calcd. for C^^H2 2 NOCl requires 
C, 67.27; H, 8.28; N, 5.23%:
Found: C, 66.87; H, 8.55; N, 5.23%.
2-Cyano-5,9-dimethyl-6,7-benzomorphan (5.7)
To a stirred, ice-cooled solution of CNBr (4.76 g ) in dry 
chloroform was added a solution of 2 ,5,9-trimethyl-6,7-benzo­
morphan (7.0 g) in chloroform (100 ml) during 15 min. The mixture 
was stirred at room temperature for 1 hr and then heated under 
reflux for 2 hr. The solvent was evaporated, and the residue 
was treated with a mixture of water (50 ml) and ether (100 ml). 
The ether layer was separated and the canbined ether layer and 
ether washings (2 x 50 ml) of the aqueous layer were washed 
successively with water (2 x 50 ml), 2N HCl (2 x 50 ml), 10% aq. 
NagCOg (2 X 50 ml) and dried (Na^SO^). Removal of the solvent 
in vacuo gave the 2-cyano compound as an oil (5.60 g ; 76%) 
which solidified on standing after purification on a column of 
silica
V (Nujol): 2220 cm  ̂ (-CEN) max
^^C n.m.r. spectrum: -CEN 118.32 ppm
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2- (N* -Phenylamidino) -5,9-dimethyl-6,7-benzomorphan (5.8)
This is a general procedure for other 2-arylamidino-6,7- 
benzomorphans .
A mixture of 2-cyano-5 ,9-dimethyl-6,7-benzomorphan (1 g;
4.5 mMol) and anilinium p-toluene sulphonate (1.26 g; 4.5 mMol) 
was heated under reflux in a mixture of pyridine (0.70 g) and 
toluene (5 ml) for 3 hr. The solvent was removed in vacuo and 
the residue was taken up in aqueous ethanol. The aqueous ethanolic 
solution was basified with 20% NaOH and extracted with ether 
(3 X lOO ml) . The combined ether extract was dried (Na^SO^) and 
removal of solvent gave 1.20 g of the crude product. Extraction 
of this crude with petroleum spirit (60 - 80) and silica column 
chrorrfitography, gave the product as an oil (0.90 g ; 63%) which 
solidified on standing. The base crystallised as needles from 
petroleum spirit (60 - 80) and had m.p. 140 - 142°C.
Anal, calcd. for ^21^25^3 
C, 78.99; H, 7.83; N, 13.16%:
Found: C, 79.03; H, 8.00; N, 13.25%.
The hydrochloride separated as colourless crystals from
ethanol-ether mixture and had m.p. 234 - 237°C.
+ — XV (KBr): C=NH 1660 cmmax y
Anal, calcd. for ^21^26^3^^ requires 
C, 70.83; H, 7.30; N, 11.80:
Found: C, 70.33; H, 7.49; N, 11.78%.
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2» (N.*-p-tolylamidino)-5,9-dimethyl-6,7-benzomorphan (5.9)
By the method described for (5.6), p. 169, 2-cyano-5,9-dimethy1-
6 .7-benzomorphan (Ig, 4.4 mMol) and p- toluidinium-p-toluene sulphonate 
(Ig, 4.9 mMol) afforded the titled product as an oil (0.73g; 50%) which 
solidified on standing. The base crystallised as tiny needles from 
petroleum spirit (60-80^0) and had m.p. 150-151°C. Anal, calcd. for 
^22^27^3 requires:
C, 79.20; H, 8.10; N, 12.61%;
Found: C, 78.15; H, 8.07; N, 12.37%
The hydrochloride separated from ethanol ether mixture and had 
m.p. 238-240°C. Anal, calcd. for *^22^28^3^^ requires:
C, 71.45; H, 7.57; N, 11.36%;
Found: C, 70.61; H, 7.13; N, 11.26%
2- (N'-p-anisylamidino)-5,9-dimethyl-6 ,7-benzomorphan (5.70)
By the method described for (5.6) p. 169, 2-cyano-5,9-dimethyl-
6 .7-benzomorphan (Ig; 4.4 mMol) and p-anisidinium-p-toluene sulphonate 
(14.5g, 4.9 mMol) gave the product as an oil (0.30g, 20%). The 
hydr'ochloride separated as tiny needles from ethanol-ether mixture and 
had m.p. 188-190°C. Anal, calcd. for ^22^28^3^^^ requires:
C, 68.48; H, 7.26; N, 10.89%;
Found: C, 65.92; H, 7.32; N, 10.46%.
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Attempted Synthesis of 2-amidino-5,9-dimethyl-6,7-benzomorphan (5,6)
A solution of 5,9-dimethyl-6 ,7-norbenzomorphan (Ig, 5 mMol) and 
2-methyl-2-thiopseudourea sulphate (0.8g, 2.8 mMol) in 50% aqueous 
ethanol (50ml) was heated under reflux for 4 hr. After the removal of 
the solvent in Vacuo, the oily residue was taken up in water, basified 
with aqueous ammonia and extracted with chloroform (3 x 50ml). Removal 
of the chloroform afforded an oil (0.80g).
and n.m.r. spectra of the product was consistent with 
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